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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
Rheumatoid arthritis is a chronic systemic inflammatory autoimmune disease primarily 
characterized by a bilateral symmetrical polyarticular arthritis, which is often erosive. It is 
probably the most common autoimmune disease (about 1% of the world population), affects 
three times as many women as men, and usually appears in middle age [1]. 
 
Although the etiology of RA remains unknown, it is widely accepted that multiple 
accumulative/compounding genetic and environmental ‘hits’ are required between the 
initiation of self-peptide recognition, subsequent loss of tolerance, and the development of 
autoimmunity [2]. Disease onset is often insidious, initially affecting the small joints of the 
hands (proximal interphalangeal joints), feet, and wrists. 
Clinical course of the disease varies between individuals but may be mild, relapsing–
remitting, or progressive. 
The systemic complications and the severity of articular manifestations (with associated 
functional impairment) may have a debilitating and disabling impact on the patient, causing 
significant morbidity, reduced quality of life, and even premature mortality. It is therefore 
important that the disease is diagnosed and treated early to slow/stop joint damage, 
increase/maintain joint function, establish remission, and maximize quality of life. It has also 
been widely reported that, although the early stages of the disease are responsive to disease-
modifying anti-rheumatic drugs (DMARDS), once the clinical disease is established, this 
effect is lost [3]. 
RA is currently diagnosed using the American College of Rheumatology (ACR) 1987 revised 
criteria [4] that are primarily based on clinical parameters, the only serological criteria being 
IgM RF. However, the criteria may be insufficient for the diagnosis of early RA, as they are 
based upon measurements for disease classification predominately featuring manifestations 
typical of later-stage disease. 
Diagnosis may be complicated by the insidious (and sometimes nonspecific) onset of the 
disease, resulting in delayed diagnosis, often to the detriment of the joint. 
Numerous serological markers of RA have been described [5] over the past half century, and 
namely rheumatoid factor (RF) and antibodies against a range of citrullinated proteins 
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including anti-perinuclear factor, anti-keratin antibody, anti-filaggrin antibody (AFA), and 
anti-Sa (vimentin) antibody. However, many others have been discarded in the routine clinical 
setting due to their lack of sensitivity, specificity, and/or laborious detection methods. An 
ideal marker would be sensitive, specific, detectable in early disease and prognostic, enabling 
clarification of disease subsets and the early identification of patients likely to develop severe 
disease and therefore requiring aggressive early treatment to prevent significant joint damage. 
Equally, patients with transient/mild arthritis would be spared unnecessary 
immunosuppressive therapy and its associated side effects, also representing a cost saving. 
The candidate marker should also be quantitative, to allow monitoring of disease (as anti-
dsDNA antibodies in systemic lupus erythematosus, SLE) and measurement of response to 
treatment. 
 
EPIDEMIOLOGY OF RA 
 
Several prevalence and incidence studies of RA have been reported during the last decades 
[rev. in 6], suggesting a considerable variation of the disease occurrence among different 
populations. The majority of prevalence studies carried out in Northern European and North 
American areas estimate a prevalence of 0.5–1.1%. Studies from Southern European countries 
report a prevalence of 0.3–0.7%. Studies from developing countries also report a relatively 
lower prevalence of the disease (between 0.1% and 0.5%). A higher prevalence has been 
reported in certain Native Americans, and a very low frequency of RA in some areas of rural 
Africa [7]. 
Table 1 presents prevalence data for RA in different population groups. These populations 
have been divided into those with high, intermediate and low prevalence rates of the disease 
which closely agree with the geographic area in which they are located. 
The annual incidence rates of RA vary between 20 and 50 cases per 100,000 inhabitants in 
North American and North European countries. There are only few studies from Southern 
European countries indicating a relatively lower occurrence of the disease. There are no 
studies on RA incidence from developing countries [8-13]. 
Mortality rates are higher among RA patients than in the general population. The mortality 
rates reported vary widely among studies. They are higher in hospital-based studies and 
relatively lower (but still higher than in the general population) in population-based studies. 
The expected survival of RA patients is likely to decrease 3–10 years according to the severity 
of the disease and the age of disease onset. The causes of death do not differ significantly 
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between RA patients and the general population they come from. It can be said that the 
majority of affected individuals die from the same causes as the general population, but at a 
younger age [6]. 
 
POPULATION  PREVALENCE INCIDENCE 
High Prevalence    
 Yakima Indians, USA 6.0 
 Chippewa Indians, USA 5.3 
 Pima Indians, USA 5.3 
0,09-0,89 
Intermediate prevalence    
North Europe    
 Denmark 0.9  
 England 1.1 0.02-0.04 
 Netherlands 0.9 0.05 
 Sweden 0.9  
 Norway 0.4-0.5 0.02-0.03 
 Finland 0.8 0.03-0.04 
South Europe    
 France 0.6 0.01 
 Italy 0.3  
 Spain 0.5  
 Portugal 0.3  
 Greece 0.3 0.02 
North America    
 USA 1.0 0.02-0.07 
South America    
 Brazil 0.6  
 Colombia 0.1  
 Jamaica 1.9  
Low prevalence    
Asia    
 China 0.3  
 Indonesia 0.3  
 Japan 0.3 0.04-0.09 
 Pakistan 0.1  
 Philippines 0.2  
Middle East    
 Egypt 0.2  
 Israel 0.3  
 Oman 0.4  
 Turkey 0.5  
Africa    
 Nigeria 0  
 Lesotho 0.2  
 South Africa (rural) 0  
 
Table 1. Prevalence and incidence data for RA in different population groups 
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RISK FACTORS 
 
There is a general consensus that RA is a multifactorial disease, resulting from the interaction 
of both genetic and environmental factors, which contribute to its occurrence and expression 
[1-3]. 
Several environmental factors have been suspected and studied as possibly related to an 
increased risk of RA, as well as to a worse or improved prognosis of the disease. However, 
the impact of most of these factors on the risk of developing RA and the expression of the 
disease remains uncertain. On the other hand, there is epidemiologic evidence that genetic 
factors are related to an increased risk of RA. The nature and the impact of this genetic risk is 
becoming clearer during the last years. We describe here the most important personal, 
lifestyle, environmental, and genetic factors that have been proposed and studied as 
influencing the occurrence of the disease. Some of these factors have also been studied as 
possibly associated with the course and the severity of RA. 
 
Genetic factors  
There is evidence that the occurrence and the severity of RA are determined by genetic 
factors. Twin and family studies strongly suggested that the risk of the disease among 
relatives of affected individuals is influenced by shared genetic factors [rev. in 14, 15, 16] 
Studies carried out in Caucasian patients with established and advanced disease indicated an 
association of RA with HLA alleles encoding a “shared epitope” (called “rheumatoid 
epitope”). These studies also suggested a significant association of “shared epitope” with 
disease severity, autoantibody production and outcome. The role of other genes has also been 
studied and several associations have been described. Some studies indicate an association 
between certain tumor necrosis factor alpha alleles and RA occurrence and severity, but 
others failed to confirm those associations. A number of DR specificities have been reported 
to be protective factors of RA. Interactions between genes in the etiology of RA have also 
been proposed. 
At the moment, it is not clear whether genetic factors are related to the risk of RA or to the 
severity of the disease or both of them. Although the available data do not clarify completely 
the role of genetic factors in disease susceptibility and severity, their impact on the 
epidemiology of RA is generally accepted. The significant variations observed in the 
incidence and prevalence of RA among different populations or ethnic groups could partly 
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been explained by genetic variation in the HLA region, and variation in the prevalence of 
“shared epitope” in different populations. 
 
Infectious agents 
A potential involvement of infectious agents in the occurrence of RA has been suggested and 
studied for decades [rev in 17]. It is possible that those agents could trigger the development 
of the disease in a genetically susceptible host. Several infectious agents have been implicated 
in the etiology of the disease, but there is not epidemiological evidence that those agents 
could explain a considerable fraction of RA cases. 
Several potential associations of RA with infectious agents have been suggested [17]. They 
include parvovirus, rubella virus, Epstein–Barr virus, borrelia burgdorferi, and others. 
Increased titers of antibodies among RA patients and clinical syndromes similar to RA 
induced by some of these agents have been reported. However, the role of infectious agents in 
the occurrence of the disease remains unclear. Incident cases of RA do not report a history of 
increased number of infections, or any specific infection. Furthermore, cases of RA do not 
present any time or space clustering, as would be expected if there was a direct association of 
RA development with infections. 
 
Age and gender 
The incidence of RA is higher in women than in men [18, 19]. The sex ratio varies in most 
studies from about 2:1 to about 3:1. This difference suggests an influence of reproductive and 
hormonal factors in the occurrence of the disease. However, the findings of several studies 
give a conflicting picture on this issue. For the moment, it is not clear how gender influences 
the occurrence of RA [18, 19]. 
The age of disease onset presents a peak in the fifth decade of life according to the majority of 
epidemiological studies. Some more recent studies suggest a later onset of the disease [20, 
21]. 
 
Smoking 
Smoking is likely to influence the risk of developing RA, the production of RA specific 
autoantibodies and the course of the disease [22]. The increased risk of RA associated with 
smoking has been suggested in cross-sectional as well as in longitudinal studies. The 
association appears to be dose-dependent, and is most clear for heavy smokers. The severity 
and the outcome of RA appears also to be influenced by smoking, although it is not clear 
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which clinical characteristics of the disease are related to smoking. An increased risk for 
seropositive disease is also related to smoking habits [23] 
. 
 
Socioeconomic factors 
Socioeconomic factors appear to influence the course and the outcome of RA rather than the 
risk of developing RA. Occupation, educational level, marital status, and social group have 
been studied as possible risk factors for disease susceptibility, or predictors for disease 
severity and outcome. The results of these studies are conflicting mainly as far as the impact 
of socioeconomic factors on the risk of developing RA is concerned. However, the available 
data suggest an association of adverse socioeconomic status with worse prognosis of the 
disease [24, 25]. 
 
Hormonal factors 
The higher occurrence of RA in females than in males suggests a possible role of hormonal 
factors in disease susceptibility [25, 26]. Furthermore, estrogens are known to have a 
stimulatory effect on the immune system. Epidemiological studies tried to investigate this 
association by studying the possible protective role of pregnancy, the use of oral 
contraceptives and the hormone replacement therapy after menopause. 
Parity has been associated with reduced risk of developing RA. However, it is difficult to 
clarify whether this association reflects any protective effect of pregnancy or an increased risk 
for infertility before the development of RA. There is also evidence that pregnancy is 
associated with remission of the disease in RA patients [27]. This effect reverts in the post-
partum period. 
The potential protective effect of the use of oral contraceptives has been studied also. It seems 
that oral contraceptives have a modulatory effect, protecting mainly against severe disease 
rather than protecting against RA occurrence. There are only few studies on the effect of 
hormone replacement therapy, presenting a conflicting picture. 
 
Dietary factors 
Several epidemiological studies suggest a potential protective effect of lifelong consumption 
of fish, olive oil, and cooked vegetables. The protective role of fish consumption has been 
attributed to the effect of omega-3 long chain polyunsaturated fatty acids against poly-
inflammatory disease. Mediterranean diet as a whole has also been reported as a lifestyle 
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factor reducing the risk of developing RA, and protecting against severe course of the disease. 
These observations could partly explain the geographical variations of the disease occurrence, 
and severity. 
 
Ethnicity 
Differences in the occurrence and the clinical expression of RA among different populations 
have been reported. The significant geographic variations of the disease occurrence, and the 
increased incidence observed in some specific ethnic groups, suggest an association of RA 
with ethnicity. The differences observed may reside in the different distribution of 
environmental and genetic factors, as well as in their interaction. Lifestyle factors possibly 
associated with the risk and the severity of RA (such as dietary factors) may differ 
significantly among ethnic groups. The prevalence of rheumatoid epitope is likely to present 
important variations in different racial groups. In addition, the association of rheumatoid 
epitope with the development of erosive disease seems to present significant differences 
among ethnic groups. These observations indicate that ethnicity could be considered as an 
independent risk factor, reflecting interactions between several genetic and environmental 
factors. 
 
 
 
HISTORY OF RA 
 
 
Did RA exist in the ancient world? 
No medical writings has been discovered with descriptions of rheumatoid arthritis until the 
seventeenth century, when Thomas Sydenham (1624– 1689) gave a fairly reasonable account, 
publishing the first case report in 1676. 
However, if the first description of RA dates from the seventheenth century, paleontological 
findings suggest that RA may be an ancient disease. 
This hypothesis is supported by the discovery of skeletal remains of American Indians that 
lived 3000-5000 years ago in Alabama. In some of these skeletons symmetrically distributed 
joint erosions, characteristic of RA, could be observed [27]. 
In the tenth century the Bizantine historian and philosopher Michael Psellus, in his 
Chronographia, described the emperor Constantine IX joints, suggesting he suffered from 
severe RA : “I myself saw his fingers, once so beautiful formed, completely altered from their 
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natural shape, warped and twisted with hollows here and projection there, so that they were 
incapable of grasping anything at all. His feet were bent and his knees, crooked like the point 
of a man’s elbow, were swollen, making it impossible for him to walk steadily or to stand 
upright for any length of time [28] 
However, Psellus also records that the Emperor was ‘naturally inclined to sexual indulgence 
but could find no satisfaction in cheap harlotry’, This might suggest that the Emperor suffered 
from a reactive arthritis (Reiter’ s disease) which can lead to severe joint destruction. 
An argument in favour of the existence of RA in the Old world comes from paintings by 
Dutch and Flemish painters. The most convincing was the joint changes in the fingers of the 
serving maid in the painting, The Printer’s Family, by Jacob Jordaens (1593– 1678). Another 
painting suggesting the existence of RA is “The Three Graces” (1638), by Paul Rubens 
(1577-1640), showing a right hand clumsily represented for some but deformed by 
rheumatoid arthritis for others. Moreover, in the painting “The Miracle of Saint Ignatius 
Loyola”, 1618 swelling of the metacarpophalangeal and interphalangeal joints can be 
observed. 
Presently, the most prevalent hypothesis is that rheumatoid arthritis originated in the New 
World, and spread to the Old World after Columbus discovered America in 1492. 
Thus, it is likely that rheumatoid arthritis had been present as a disease for a long time, maybe 
since the time of Sydenham (1624-1689), but the nomenclature had been confused with terms 
like rheumatic gout, chronic rheumatism, rheumalgia, scorbutic rheumatism, etc. 
Actually, the first precise description of RA date from the end of the eighteenth century.  
In 1782, Jon Petursson described a chronic, symmetric, destructive, inflammatory 
polyarthritis different from osteoarthritis and sometimes accompanied by systemic 
manifestations [29].  
The first surely unambiguous report of rheumatoid arthritis is considered the description that 
the young Parisian doctor named Augustine Jacob Landrè-Beauvais made in 1800 writing his 
MD thesis [30].  
After reviewing the main features of ordinary and regular gout, the scientist pointed out that 
the disease he named “asthenic gout” exhibited several distinctive features, including 
predominance in women, a chronic course, involvement of main joints at the onset, and 
decline in general health. He was convinced that he has being describing an yet unreported 
entity.   
Nevertheless, the name “rheumatoid arthritis” was only given in 1859 by the English 
Physician Alfred Baring Garrod, considered as “the father of rheumatology”, who discussed 
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the differential diagnosis of rheumatoid arthritis with respect to different other conditions like 
rheumatic gout, chronic rheumatism, rheumalgia, scorbutic rheumatism. He rejected previous 
definitions like “chronic rheumatism” and “rheumatic gout” and chose the name “rheumatoid 
arthritis”. Moreover he divided the disease in acute, chronic and irregular forms of 
generalized and localized type [31].  
The name has remained ever since. 
 
 
PATHOLOGY 
 
The histologic changes in RA are not disease-specific but largely depend on the organ 
involved. The primary inflammatory joint lesion involves the synovium [1, 2, 3]. In contrast 
to hematogenous infective arthritis, synovial changes are a primary event an do not follow 
changes in the adjacent bon marrow. The earliest changes are injury to the synovial 
microvasculature with occlusion of the lumen, swelling of endothelial cells and gaps between 
endothelial cells. This stage is usually associated with mild proliferation of the superficial 
lining cell layer. Two cell types constitute the synovial lining: a bone marrow derived type A 
synoviocytes, which has macrophagic features and the mesenchimal type B synoviocytes. 
Both cell types contribute to the synovial hyperplasia, suggesting a paracrine interaction 
between these two cell types. This stage of inflammation is associated with congestion, edema 
and fibrin exudation. Cellular infiltration occurs in early disease and initially is mainly 
represented by T lymphocytes. The nodular aggregates consist mainly of CD4+ T cells, while 
CD8+ T cells dominate in the diffuse infiltrate. Close cell-to-cell contact with dendritic cells 
and macrophages has been described. In later stages true lymphoid follicles with germinal 
centers may appear, although rheumatoid synovitis presents with a diffuse lymphocytic 
infiltrate without follicles or pseudofollicles in many patients. Plasma cells are usually found 
in more advanced stages of inflammation. 
As a consequence of inflammation the synovium becomes hypertrophic from the proliferation 
of blood vessels and synovial fibroblasts and from multiplication and enlargement of the 
synovial lining layers.  
Granulation tissue extends to the cartilage and is known as pannus. The tissue actively 
invades and destroys the periarticular bone and cartilage at the margin between synovium and 
bone. 
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Clinically evident extra-articular manifestations occur in approximately 20% of RA patients, 
although sub-clinical involvement is likely to be more frequent. Rheumatoid nodules have the 
histologic appears of a foreign body granuloma with three distinct layers. Multicentric 
fibrinoid necrosis is sourrounded by palisading elongated cells arranged radially and 
granulation tissue with inflammatory cells. The composition of necrotic material varies. No 
conclusions about the necrosis-inducing events can be drawn from histologic examination, but 
since nodules often occur over pressure points, minor trauma may precipitate the necrosis. 
The elongated cells are modified macrophages that are aligned parallel to collagen fibers. 
Tenosynovitis is present in the majority of patients. Involvement of the tendons themselves is 
common and manifests as a non specific inflammatory infiltrate and less frequently as 
formation of characteristic nodules with central necrosis. 
Vascular involvement is usually confined to small segments of terminal arteries and lacks 
distinctive histologic characteristics. 
In general immune complex deposition may contribute to, but does not explain completely, 
the spectrum of extra-articular manifestations. A common theme appears to be the 
mononuclear cells infiltrate with varying degrees of fibrinoid necrosis and nodule formation. 
 
 
 
 
 
 
 
DIAGNOSIS OF RA 
 
Given the seriousness of the disease, an early and accurate diagnosis of RA is mandatory. 
The 1987 ACR (American College of Rheumatology) criteria for the classification of RA [4] 
are commonly used for its diagnosis and are listed in the following table. 
For classification purposes, a patient is said to have RA if he or she has satisfied at least 4 of 
the following 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. 
Patients with 2 clinical diagnoses are not excluded. 
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CRITERION DEFINITION 
Morning stiffness Morning stiffness in and around the joints, 
lasting at least 1 hour before maximal 
improvement 
Arthritis of 3 or more joint areas for at least 6 
weeks 
At least 3 joint areas simultaneously have had 
soft tissue swelling or fluid observed by a 
physician. The 14 possible areas are right or 
left proximal interphalangeal (PIP), 
metacarpophalangeal (MCP), wrist, elbow, 
knee, ankle, and metatarsophalangela MTP 
joints  
Arthritis of hand joints for at least 6 weeks At least 1 are swollen in a wrist, MCP or PIP 
joint 
Symmetric arthritis Simultaneous involvement of the same joint 
areas (as defined in criterion 2) on both sides 
of the body 
Rheumatoid nodules Subcutaneous nodules, over bony 
prominences, or exterior surfaces, or in 
juxtaarticular regions, observed by a physician 
Serum rheumatoid factor Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which 
the results has been positive in less than 5% of 
normal control subjects 
Radiographic changes Radiographic changes typical of RA on 
postero-anterior hand and wrist radiograph, 
which must include erosion unequivocal bony 
decalcification localized in or most marked 
adjacent to the involved joints 
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CHAPTER 2 
 
Anti-Citrullinated Peptide/proteins Antibodies in RA 
 
 
AUTOANTIBODIES IN RHEUMATOID ARTHRITIS 
 
A number of autoantibodies have now been described in RA and their clinical associations 
and role as markers of disease examined [1]. Of these only three (rheumatoid factors (RFs), 
antibodies to citrullinated antigens such as fillagrin and anti-CCP antibody [2], and antibodies 
to immunoglobulin binding protein (BiP) [3] have shown sufficient sensitivity and specificity 
to be considered clinically useful, and only two (RFs and anti-CCP antibody) are used in 
clinical practice. 
 
Rheumatoid Factor 
RFs, the first described human autoantibodies [4] are directed at the Fc region of IgG and are 
usually of IgM isotype. They are detectable in up to 10% of normal individuals, 70–80% of 
patients with RA and in other systemic diseases such as Sjogren's syndrome and many 
systemic infections [5]. RFs and the B cells that synthesise and secrete them are believed to 
have a physiological role as part of the immune system. However RFs from healthy 
individuals and patients with RA differ considerably. RFs in healthy individuals are 
synthesised by CD5 + B cells, exhibit low affinity for IgG, polyreactivity and a low ratio of 
replacement to silent mutations in their CDRs [6 and 7] suggesting the presence of a 
mechanism to suppress the affinity maturation of RFs. In rheumatoid synovium, B cells 
produce high affinity RFs with multiple replacement mutations in their CDRs, indicating a 
process dependent on T cell help affinity maturation. In addition synoviocytes themselves can 
support the survival and differentiation of B cells [8]. Hence in RA synovium RF-producing 
B cells could encounter a milieu that would support their survival and provide the T cell help 
necessary for the production of high affinity RFs [9]. There is evidence that they could 
contribute to disease by the formation of immune complexes [10] and complement fixation 
[11], and also by functioning as highly efficient antigen-presenting cells [12]. The correlation 
of RF status and progression of joint damage in RA [13] supports a role in pathogenesis 
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although they are by no means an absolute requirement for severe disease and joint 
destruction. 
 
 
Type II collagen and other components of articular cartilage 
The idea that immune responses directed against joint-related antigens may play a role in the 
pathogenesis of RA has been pursued for many years. The possible importance of immune 
responses to type II collagen (CII) was first suggested nearly 30 years ago. The specific 
expression of this molecule in articular cartilage as well as its ability to induce a destructive 
arthritis in experimental animals made it an attractive candidate autoantigen in human RA. 
Antibodies to native and denatured CII have been demonstrated in serum of patients with RA 
(10–30%) [14] as well as in synovial fluid, and collagen–anticollagen immune complexes 
described in synovial tissue [15]. A dominant epitope of anti-CII antibodies has been 
identified [16]. T cell responses have been found in approximately 50% of antibody positive 
patients [Snowden N, Reynolds I, Morgan K and Holt L. T cell responses to human type II 
collagen in patients with rheumatoid arthritis and healthy controls. Arthritis Rheum.1997; 40: 
1210–1218]. Antibodies to CII are present early in the disease course, appear to decline with 
time and may be predictive of a more severe outcome [17]. However, T cell responses to CII 
are also found in 37% of normal individuals [18], many patients do not demonstrate any form 
of immune response to CII and no major associations with clinical parameters have been 
described. Attempts to induce tolerance in patients with RA by the oral administration of 
collagen have met limited success [19]. Hence the relevance of anti-CII T cell responses and 
autoantibodies remains unclear. 
 
 
Anti-RA33 or anti-hnRNP A2 
Antibodies to the 33 kDa A2 protein of the heterogeneous nuclear ribonucleoprotein complex 
(anti-RA33 or anti-hnRNP A2), a component of the spliceosome, were first demonstrated in 
approximately 35% of patients with RA by Western blotting [20]. They are not disease-
specific, however, occurring in 20% of patients with SLE and 40–60% with MCTD, usually 
concomitantly with antibodies to U1-snRNP or Sm; these latter antibodies do not occur in RA 
[21]. The major autoantibody binding sites have been shown to be conformation-dependent 
and found to be different in MCTD patients from RA and SLE [22]. Interestingly anti-RA33 
has been shown to occur in two experimental models of arthritis, in TNF-transgenic mice [23] 
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and in the arthritis prone MRL/lpr mice [24]. The presence of anti-RA33 in SLE appears to 
define a subset of patients with destructive arthritis emphasising the link with joint pathology 
[25]. Although shown to be present early in the disease, anti-RA33 has not been shown to 
have any predictive value for disease severity or progression. 
 
 
Antibodies to calpastatin 
Calpastatin is a natural inhibitor of the calpains, a family of intracellular calcium-dependent 
cysteine proteases unique because of their cytosolic rather than lysosomal location. Calpains 
are over-expressed in diseased synovial tissue [26] and secreted calpains can degrade 
components of articular cartilage [27]. Two groups independently described antibodies to 
calpastatin in approximately 50% of RA sera and although not specific for RA they occur at a 
higher frequency than in connective tissue diseases [28 and 29].  
 
It has therefore been postulated that autoantibodies to calpastatin may potentiate joint 
destruction by interference with the calpain–calpastatin interaction [30]. Some support for this 
hypothesis comes from the in vitro observation that calpains are released from calpain–
calpastatin complexes in the presence of RA sera [31]. Antibodies to calpastatin however are 
not associated with disease severity, and more recent studies have suggested they may be less 
frequent than previously believed [32]. The importance therefore of anti-calpastatin antibodies 
in RA remains unclear. 
 
 
Antibodies to stress proteins 
Heat shock proteins and BiP, a 78 kDa chaperone are members of a highly conserved family 
of proteins with critical roles in cellular homeostasis in both normal conditions as well as 
during cellular stress [33]. The close homology between bacterial and human HSPs suggested 
the possibility that molecular mimicry arising from cross-reaction of anti-bacterial HSP 
responses with the human counterpart might play a role in disease pathogenesis. Many studies 
in the early 1990s identified antibodies to the human heat shock proteins HSP-65, -70 and -90 
in subjects with RA as well as a number of other diseases and healthy controls, however the 
inconsistent data obtained and lack of disease specificity did not support the initial enthusiasm 
for this idea [34]. Indeed T cell responses to heat shock protein derived epitopes were found 
to be immunoregulatory rather than disease-potentiating in experimental models [35]. In 
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addition BiP is over-expressed in the rheumatoid joint and is present in both early and pre-
disease sera [36]. Finally BiP itself may have immunomodulatory properties quite apart from 
its role as an antigen [37] and therefore may represent a novel therapy in itself. 
 
 
Anti-Sa antibodies 
An RA-specific autoantibody was discovered in 1994 and named after a patient as anti-Savoie 
(anti-Sa) [38]. This antibody was present in the sera of 43% of RA patients but not in many 
other autoimmune diseases and in healthy individuals. In addition, 27% of RF negative RA 
patients also tested positive for anti-Sa. Using immunoblot technique, anti- Sa reacted with a 
50 kDa protein present in the spleen, placenta, as well as in the RA synovium. Numerous 
studies have been performed since that time, and the overall specificity of anti-Sa was found 
to be 92–98%, whereas the sensitivity was about 40% [39]. The high specificity is coupled 
with substantial prognostic value [40 and 41], as anti-Sa positivity has been associated with 
more active and destructive disease [42]. Thus, anti-Sa has been thought to have important 
diagnostic and prognostic relevance in RA. 
 
 
Recently, Sa has been identified as modified form of vimentin, with anti-Sa autoantibodies 
only found to target modified vimentin and not the native form [43]. Vimentin is an 
intermediate filament protein, one of the cytoskeletal proteins providing structural support in 
mesenchymal cells. The protein is normally unmodified but converted during cell death and 
tissue inflammation. Anti-Sa antibodies were found to be predictive of poor outcome in RA, 
characterized by more rapid development and more severe joint damage [44]. 
 25
ANTI CITRULLINATED PROTEINS/PEPTIDES ANTIBODIES (ACPA) 
 
 
HISTORY OF ACPA 
 
Among the above mentioned autoantibodies, the only serological test routinely used is to 
determine the presence of rheumatoid factors (RF) in the serum. RF are antibodies directed to 
the constant region of immunoglobulins of the IgG subclass, and their presence is determined 
by agglutination assays, nephelometry, or ELISA-based tests. RF can be detected in up to 70–
80% of RA patients, but is also detected in relatively high percentages in other autoimmune 
and infectious diseases, and in up to 15% of healthy individuals, especially elder people [45]. 
Antibodies of a more specific nature have also been found in the sera of RA patients. 
In 1964 Nienhuis and Mandema discovered that  RA patient sera contain highly specific 
antibodies named anti perinuclear factor antibodies (APF) [46]. 
 
These antibodies specifically label the perinuclear factor, a component of a number of so-
called keratohyaline granules surrounding the nucleus, in indirect immunofluorescence (IIF) 
using buccal mucosa (BM) cells. These antiperinuclear factor (APF) antibodies are reported to 
be present in 49–91% of RA patients with a specificity between 73 and 99% [47]. Not every 
BM cells donated are suitable as an antigenic substrate. A high percentage of APF-positive 
BM cells can only be found in 5% of the donors. 
This dependence on the availability of suitable donors and the inconvenience of the IIF test 
format are the main reasons why the APF test is not routinely used. Anyway APF are 
produced in the initial phases of the disease and could be used for an early diagnosis, being 
present in 20% of RA patients before clinical manifestations. 
In 1979, Young et al. described the presence of anti keratin antibodies (AKA), whose 
presence can be determined by IIF on cryosections of the stratum corneum of rat esophagus 
epithelium [48]. The sensitivity of the AKA test varies between 36 and 59%, with a 
specificity between 88 and 99% [49]. Again, the presence of AKA is not routinely tested 
because of the inconvenient antigenic substrate and the use of IIF that is regarded as a 
problem in a routine laboratory setting. 
The nature of the antigen recognized by both the AKA and APF antibodies has been unclear 
until 1993, when Simon et al. showed that the target of AKA is filaggrin, a filament protein. 
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It was shown that the APF and a monoclonal antibody specific for human profilaggrin 
produce an identical staining pattern in IIF [50]. 
A 40-kD protein extracted from human epidermis, specifically labeled by RA sera in Western 
blots, was identified as a neutral/acidic isoform of filaggrin [51]. Moreover, it was 
demonstrated that the IgG fraction, affinity-purified from patient sera by using the 40-kD 
protein, was reactive in both the APF and AKA test, indicating that the AKA and APF 
antibodies are at least partially overlapped [52]. 
 
Filaggrin (filament-aggregating protein) is produced during the late stages of terminal 
differentiation of epithelial cells in mammals. It is synthesized as a heavily phosphorylated 
precursor protein (profilaggrin) that consists of 10–12 filaggrin repeats [53]. Profilaggrin is 
deposited in granules, and filaggrin is released by proteolytic cleavage during differentiation 
of the cells. During this stage the protein is dephosphorylated, and 20% of the arginine 
residues are converted into citrulline by the enzyme peptidylarginine deiminase. The large 
heterogeneity in amino acid sequence of filaggrin (30–40% of the amino acid residues of the 
filaggrin repeat units are variable) and the partial citrullination of arginine residues result in 
an extensive charge heterogeneity. 
Anti filaggrin antibodies do not bind the precursor or the non deiminated form of the 
molecule, but react only towards filaggrin deiminated either in vitro or in vivo [54]. 
Thus, citrullyl residues are an essential constituent of epitopes recognized by these 
autoantibodies. In 1998, Schellekens et al. showed that AFA bind filaggrin derived synthetic 
peptides, where arginine has been substituted by citrulline during in vitro synthesis [55]. 
A high percentage of RA sera reacts with one or more modified peptide and generally the 
presence of two citrulline increases the antigenicity.  
Moreover, further improvement in antigenicity has been reached by inserting two cysteine 
residues at the tails of the peptide and oxidizing them, thus creating a cyclic citrullinated 
peptide (CCP), employed in the anti-CCP1 diagnostic assay [56]. 
The anti-CCP antibody (CCP2) assay was developed using a mixture of synthetically formed 
cyclic citrullinated peptides, which show no homology to tissue proteins and were generated 
using RA sera to screen citrullinated peptide libraries (14 million peptides). The cyclic 
structure (formed with disulfide bonds) provides optimal exposure of the citrulline residues, 
enhancing recognition of the peptide by the autoantibodies and therefore increasing the 
sensitivity of the assay. 
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Anti-CCP antibodies are highly specific for RA and may appear many years before the onset 
of symptoms. 
Typically, 50%–70% of early RA patients are anti-CCP positive [57 and 58], and the 
phenotype is thereafter very stable, i.e., very few patients shift from being anti-CCP positive 
to being anti-CCP negative or vice versa, even after treatment with disease-modifying 
antirheumatic drugs [59 and 60]. This qualitative phenotypic stability is also seen after 
treatment with TNF-blocking agents, although ACPA concentrations remain stable in some 
[61 and 62], but not in all [63 and 64] studies. Comparatively few individuals (typically 
approximately 2%) in a population of healthy controls are positive for anti-CCP antibodies. 
 
Whereas filaggrin is not present in the RA joint, this protein itself is probably not the in vivo 
target of ACPA in RA, but rather an antigen cross-recognized in vitro. Indeed, epithelial 
tissues are not particularly affected during RA and filaggrin is not expressed in articular 
tissues.  
By immunochemical analysis of exhaustive sequential extracts of rheumatoid synovial 
membranes, Masson-Bessiere et al. [65] demonstrated that these tissues contain several 
citrullinated proteins, among which only two were significantly and specifically targeted by 
ACPA. On the basis of several biochemical and immunological arguments, these two proteins 
were identified as citrullinated forms of the a- and b-chains of fibrin.  
Subsequent studies demonstrated that citrullinated fibrinogen is abundant in the inflamed 
synovium [66, 67, 68]. Using in-house assays, several studies confirmed the presence of anti 
citrullinated fibrinogen (ACF) antibodies in the sera of RA patients [69, 70, 71]. The 
diagnostic performance of the assays was very similar to that of anti-CCP2 ELISA, with a 
very high agreement rate [72]. ACF antibodies were good predictors of RA at 1 year in 
patients with early arthritis, and for radiographic progression after 1 years. An association was 
observed between HLA-DRB1*0404 alleles and the production of ACF antibodies [73]. 
 
In the recent years, Sa, an autoantigen in RA, has been identified as citrullinated vimentin, 
with anti-Sa autoantibodies only found to target citrullinated vimentin and not the native form 
[74] 
Vimentin is secreted and citrullinated by macrophages in response to apoptosis, or by 
proinflammatory cytokines, such as tumor necrosis factor-α [75 and 76]. Vimentin contains 
43 arginine residues, which can be potentially citrullinated by PAD. 
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These results suggest that citrullinated vimentin may be a newly identified, promising 
autoantigen in RA. To detect antibodies to citrullinated vimentin, a new ELISA system has 
recently been developed [77]. This assay utilizes genetically mutated citrullinated vimentin 
(MCV) to improve the performance of the test. 
When introducing a cut-off level resulting in 95% specificity, it has been observed a 69.7% 
sensitivity for the anti-MCV assay when compared with 74.8% for anti-CCP2 ELISA.  
The agreement rate between anti-MCV and anti-CCP2 tests was 88.2%. A strong correlation 
between anti-MCV and anti-CCP2 levels in RA sera has also been found, suggesting potential 
cross reactivity. However, the presence of anti-MCV positive patients in the anti-CCP2 
negative group suggests that these antibodies may be directed to citrullinated epitopes present 
only in the anti-MCV assay. 
 
Among other proteins that can be citrullinated and thus become a target of ACPA, there are 
alpha enolase, fibronectin, and nuclear proteins. 
 
Alpha-enolase is recognized in its in vitro citrullinated form by RA sera [78] 
Epitope mapping identified an immunodominant citrullinated peptide on alpha-enolase 
(citrullinated alpha-enolase peptide 1) able to detect ACPA [79]. 
Antibodies to this epitope were observed in 37-62% of sera obtained from patients with RA, 
3% of sera obtained from disease control subjects, and 2% of sera obtained from healthy 
control subjects. Binding was inhibited with homologous peptide but not with the arginine-
containing control peptide or with 4 citrullinated peptides from other portions of the molecule, 
indicating that antibody binding was dependent on both citrulline and flanking amino acids  
The immunodominant peptide showed 82% homology with enolase from Porphyromonas 
gingivalis, and the levels of antibodies to citrullinated alpha-enolase peptide 1 correlated with 
the levels of antibodies to the bacterial peptide (r2=0.803, P<0.0001). Affinity-purified 
antibodies to the human peptide cross-reacted with citrullinated recombinant P. gingivalis 
enolase.  
These data on sequence similarity and cross-reactivity with bacterial enolase may suggest a 
role for bacterial infection, particularly with P. gingivalis, in priming autoimmunity in a 
subset of patients with RA, but may also be due to the highly conservation among species of 
the sequence of enzyme such the alpha enolase. 
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Moreover, alpha-enolase can be found in the regions of the synovium staned by anticitrulline 
antibodies [80], but Western blotting of immunoprecipitates from synovial cells failed to 
confirm in vivo citrullination of alpha enolase . 
 
Fibronectin colocalizes with citrulline reactivity on parallel stainings of consecutive sections 
and on 1-dimensional Western blotting after immunoprecipitation of fibronectin [81]. 
However, as fibronectin can crosslink with fibrin, deimination of fibronectin needs to be 
confirmed by identification of the citrulline containing epitopes. 
 
Finally, immunohistochemical analysis of RA and control synovium also revealed nuclear 
staining suggesting that deiminated nuclear proteins, such as histones (known to be 
deiminated during transcriptional control processes) [82, 83, 84] may also be present. 
 
 
 
CITRULLINATION  
 
Peptide-bound arginine residues can undergo this modification and the resulting citrulline 
remains part of the protein as peptidyl citrulline. Citrulline is not a natural amino acid in 
proteins, therefore may induce immune response. The conversion of arginine (Arg) to 
citrulline (Cit) changes the charge of the amino acid. Arginine is strongly basic (pI 10.76) due 
to the presence of a guanidino group that could easily be protonated at physiological pH. The 
removal of the imino moiety (a transformation referred to as deimination) is an enzymatic 
reaction catalyzed by peptidylarginine deiminases (PAD). The resulting citrulline lacks the 
strong basic character; it is a neutral amino acid similar to Asn or Gln. 
At the protein level, the reaction leads to a 1 Da mass reduction for each Arg modified. Basic 
charge(s) are lost that will influence the overall charge, charge distribution, isoelectric point, 
as well as the ionic and hydrogen bond forming abilities of the protein [85, 86].  
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The deimination process could change the primary, secondary and tertiary structures of 
proteins. In vitro analysis revealed that high degree of citrullination could denature proteins 
[86]. Experiments with trichohyalin (THH) and filaggrin suggest that modification of 5% of 
the Arg residues starts to destroy the tertiary structure, and modification of more than 10% of 
the arginines leads to a complete loss of ordered structure, causing denaturation of the protein. 
This phenomenon could likely be attributed to the loss of basic residues resulting in altered 
charge distribution, loss of ionic interactions and H-bonds [86]. In vivo, under physiological 
conditions we cannot assume that Citrullination is a denaturation process. In general, it can be 
presumed that the modification alters the protein structure and results in a somewhat looser, 
less organised, more open configuration [86]. The deimination may also influence the 
interaction of the molecule with other proteins. The wide array of primary effects of 
citrullination leads to far-reaching physiological and pathological consequences. 
 
 
PEPTIDYLARGININE DEIMINASE (PAD) 
 
In their pioneering study in 1977, Rogers and Taylor [87] described for the first time a 
calcium-dependent enzyme involved in the deimination of a hair follicle protein. Further 
works demonstrated that deimination is catalyzed by a family of enzymes, the 
peptidylarginine deiminases (PADs) (EC 3.5.3.15). 
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Five paralogous genes encode the 5 human PAD isoforms, PADI1, 2, 3, 4 and 6. The genes 
PADI are clustered on chromosome 1p35-36, a region conserved with synteny on the mouse 
chromosome 4E1. The coding sequences of these 5 genes display 59-71% nucleotide identity 
and 45-55% aminoacid identity. Available genome data reveal the existence of the five PADs 
in mammals, of three PADs in birds (Gallus gallus), and one in amphibians (Xenopus laevis) 
and fish (Danio rerio, Takifugu rubripes and Tetraodon nigroviridis). The gene PADI2 first 
diverged from the common ancestor, has been submitted to high negative selective pressure, 
and has probably retained the ancestral biochemical function [88]. The PADI genes may have 
been fixed through specialization of expression in tissues, or neofunctionalization through 
different biochemical requirements [89, 90]. Not only the expression of the genes PADI is 
regulated at the transcriptional level (as that of PADI2 [91, 92], or PADI3 [93], but also at the 
post-transcriptional (PADI4) [94] and translational (PADI2 [92] levels. PADI2 is expressed in 
a wide array of tissues; PADI1, mainly in epidermis, prostate, testis, placenta, spleen and 
thymus; PADI3, in epidermis and hair follicles; and PADI4, in the haematological system 
[95]. PADI6 is expressed essentially in oocytes/ovary and testis, and during embryonic 
development [96]. 
 
 
PAD and RA – Expression and functions 
 
A role for PADI4 in RA has been suggested on the basis of different experimental evidences 
[rev. in Pratesi et al., Autoimm Rev. in press] 
PADI4 can be detected in synovial tissue from RA patients, in T cells and B cells (nuclei) 
surrounding small capillaries, macrophages (cytoplasm and nuclei), which are very abundant 
in the inflamed RA synovial membrane and in granulocytes (nuclei) which are evenly 
distributed in the tissue [97]. Because of this abundant inflammatory infiltrate, the PADI4 
content is  high in RA synovia. Moreover, extensive angiogenesis is a primary feature of RA 
synovial tissue: the nuclei of endothelial cells surrounding small capillaries express PADI4 
[97]. In RA synovial tissue there is a significant amount of fibrin deposition; most of these 
fibrin deposits form a solid block and some fibrin appear as a mesh or spongy structure with 
loosely organized cells: the latter expressed large amounts of intracellular and extracellular 
PADI4 protein [97]. 
The role of PADI4 in the pathogenesis of RA is still a matter of debate, and different possible 
roles of the enzyme in this disorder have been suggested. As mentioned above, the RA 
synovial membrane contains large numbers of activated macrophages, that express PAD 
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enzymes and, under certain conditions, contain citrullinated proteins. The macrophages in the 
RA synovial tissue (in RA 80–100% of synovial lining cells are macrophage-like cells, 
compared with 20–30% in normal synovium) show signs of activation; short term activated 
macrophages are protected from apoptosis, whereas long term (>24 hours) activated 
macrophages are very prone to cell death [98]. Calcium influx in the dying macrophages 
triggers activation of PAD and subsequent citrullination of several intracellular proteins. 
Furthermore, PAD enzymes may leak out of dead cells, enabling them to citrullinate 
extracellular proteins [97, 98].  
Proteins involved in the apoptotic process may be targeted by PADI4. During apoptosis, 
cytokeratins undergo caspases digestion, and this event seems fundamental for the 
morphological features of apoptosis such as cell shrinkage, nuclear fragmentation, and 
apoptotic body formation [99]. Upon citrullination, cytokeratins are resistant to the digestion 
of caspases; thus, PADI4 may in the end interfere with apoptosis [99, 100], contributing to 
synovial hyperplasia [101]. Another protein involved in the apoptotic process that can be a 
substrate for PAD is fibronectin (Fn) [81]: this protein is expressed at high levels in arthritic 
joints and it mediates various physiological processes through interactions with cell-surface 
integrin receptors and growth factors. Upon in vitro citrullination, Fn no longer stimulates the 
apoptosis of monocytes induced from cultured HL-60 cells. Thus, citrullination can modify 
the affinity of Fibronectin for its receptors and growth factors, contributing to mechanisms of 
RA pathogenesis such as perturbed angiogenesis and apoptosis [81]. 
Nonetheless, studies from Hung et al show that PADI4 is able to induce apoptosis through 
cell cycle arrest in a mythocondria mediated pathway, and that PADI4 SNPs associated with 
RA have a higher activity in inducing apoptosis of Jurkat cells [25, 37]. 
Thus, a definitive role for PADI4 in apoptosis remains to be elucidated. However, several data 
suggest a deregulation of apoptosis in RA pathogenesis, and many cell types expressing 
PADI4 are involved in the disease. PADI4 may have different effects in different cell types, 
leading to increased inflammation, tissue formation, neoangiogenesis, and finally to over-
production of deiminated proteins. 
Citrullinated proteins may lose/change their physiological functions, as in the case of 
antithrombin: this protein is involved in the control of inflammation, regulating the 
pleomorfic activities of thrombin, such as fibrin clots formation, angiogenesis induction, 
proinflammatory mediators elevation. Upon citrullination, antithrombin loses its anti-
inflammatory activity possibly contributing to the perpetuation of inflammation at the sites of 
PADI4 activity [102]. 
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CHAPTER 3 
 
Anti-Viral Citrullinated Peptides Antibodies in RA 
 
INTRODUCTION 
 
A comparative evaluation of the sequences recognized by ACPA showed that their most 
crucial feature is the presence of citrulline flanked by neutral amino acids such as glycine, 
serine, or threonine [1]. Similar amino acid repeats are often found in nucleic acid–binding 
proteins; some of these are of viral origin (e.g., the transcription-regulating proteins in 
herpesvirus) [2]. Epstein-Barr virus (EBV), a member of the Herpesviridae family, is known 
to infect human B lymphocytes and epithelial cells of the oropharynx, establishing a reservoir 
in both of these cellular compartments [3]. Moreover, a large number of other cells may be 
infected in a transient manner [4, 5, 6]. 
One of the nuclear proteins encoded by Epstein-Barr virus (EBV), EBNA I, contains in its N-
terminal region a sequence (35-58) characterized by 6 gly-arg repeats. 
In our laboratory this sequence has been synthesised as multiple antigen peptide (MAP) 
substituting arginine with citrulline (viral citrullinated peptide, VCP) to test sera from 
patients with connective tissue disorders: anti-VCP antibodies were detected in 45% of RA 
sera and in less than 5% of normals or disease controls [7]. Moreover, anti-VCP antibodies 
bound in vitro deiminated recombinant EBNA I and immunoprecipitated in vivo deiminated 
EBNA I from the lysate of EBV-infected cell lines [8]. 
 
 
 
 
 
 
 
 
 
 
 
 
A 4-branches multiple antigen 
peptide (MAP) 
The Viral Citrullinated 
Peptide (VCP) 
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Purified anti-VCP antibodies were all positive in the anti-CCP assay, and their binding was 
completely inhibited by preincubation with VCP or MAP GC (a multiple antigen peptide 
bearing 4 identical 16-aa peptides characterised by Cit-Gly repeats). Anti-VCP antibodies all 
bound the deiminated fibrinogen, whereas no binding was observed with untreated fibrinogen 
or with deiminated BSA. When tested on nitrocellulose strips containing filaggrin-derived 
deiminated peptides, anti-VCP antibodies all reacted with the 2 bands corresponding to 
deiminated peptides. 
 
Further studies were conducted to analyze the frequency of anti-viral citrullinated peptide 
(anti-VCP) antibodies in sera from patients with rheumatoid arthritis (RA), normal subjects 
and control diseases. Anti-VCP antibodies were determined in 300 RA sera, and 327 
controls including connective tissues diseases, chronic arthritides and healthy donors [9]. 
Again, anti-VCP antibodies were found in 45% of RA and in less than 5% of controls; their 
amount correlates very well with anti-CCP antibodies levels (p<0.001). 
Taken together, these results proved that anti-VCP antibodies belong to the family of ACPA 
and that VCP may be considered a diagnostic tool for the diagnosis of RA. 
Moreover, these results suggested a role for EBV infection in the induction of disease-specific 
antibodies in RA. 
Thus, other deiminated antigens of viral origins were searched 
1. to set up new ELISA assays with improved sensibility and specificity, as compared 
with anti-VCP ELISA 
2. to define new deiminated viral sequences as possible targets of immune response in 
RA 
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PATIENTS AND METHODS 
 
 
Patients 
One hundred twenty-three RA patients, diagnosed according to the ACR classification criteria 
[10], were analysed. As disease controls twenty-one ankylosing spondilytis (AS) patients, 29 
psoriatic arthritis (PsA) patients and 20 undiffferentiated arthritis (UA) patients were 
analysed. AS was diagnosed according to the revised New York criteria [11]; PsA was 
diagnosed according to the criteria of Vasey and Espinoza [12]. Other disease control subjects 
were analysed, including 21 systemic sclerosis (SSc), 21 mixed cryoglobulinaemia (MC), 29 
systemic lupus erythematosus (SLE), 35 polymyalgia rheumatica (PmR), 13 Sjogren’s 
Syndrome (SS). The diagnosis of SLE [13] and SSc [14] was based on the ACR criteria; MC 
was diagnosed in the presence of Meltzer’s triad (purpura, weakness and arthritis/arthralgia) 
and of cryoglobulins in the sera; SjS was diagnosed according to the criteria of the American 
European Consensus Group [15]. Diagnosis of infectious mononucleosis were done on the 
basis of clinical and serological evidences. 
 
Peptide synthesis.  
Peptides used in these studies were synthesized and purified by Espikem s.r.l. (Firenze, Italy) 
Briefly, peptides were obtained by solid-phase synthesis using 9-fluorenylmethoxycarbonyl–
protected amino acids, according to the method described by Merrifield [16] and modified by 
Atherton and Sheppard [17], in the form of linear peptides or as multiple antigen peptides 
(MAPs) bearing 4 identical sequences on a lysine scaffold [18]. 
The obtained peptides were at least 75% pure, as deduced from their elution pattern on 
reverse phase high-performance liquid chromatography and their relative absorption at 214 
nm. 
 
Binding of anti–citrullinated peptides/proteins antibodies 
Anti peptide antibodies were detected in the sera by ELISA, as previously described [8 and 9]. 
Briefly, the different peptides (either linear or MAP) were added to polystyrene plates (Nunc 
MaxiSorp F96; Nunc, Roskilde, Denmark) at 2-5 µg/ml in PBS and incubated overnight. 
Saturation was carried out with PBS containing 3% BSA for 45 minutes at room temperature. 
Sera diluted 1:200 in PBS containing 1% BSA and 0.05% Tween 20 (PBSBT) were incubated 
on the plates for 3 hours at room temperature. After washings with PBS–1% Tween and PBS, 
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anti-human IgG alkaline phosphatase (Sigma) conjugated 1:3,000 in PBSBT was added to the 
wells, and the plates were incubated for 2 hours at room temperature. 
Alkaline phosphatase activity was revealed with p-nitrophenyl phosphate in 50 mM Na2CO3 
(pH 9.6).  
Anti-CCP antibodies were detected with a commercial kit (QUANTA Lite CCP2, Inova 
Diagnostics, San Diego, CA), according to the manufacturer’s instructions. 
 
Purification of antibodies specific for the deiminated viral peptides from RA patients. 
Different deiminated viral peptides were conjugated to CNBr-activated Sepharose (Sigma) 
according to standard procedures. Total immunoglobulins from RA sera containing ACPA, 
were precipitated with 50% saturated ammonium sulfate; the precipitates were dissolved in 
phosphate buffer (pH 7.4) and dialyzed overnight against phosphate buffered saline (PBS). 
Enriched immunoglobulin preparations were applied to the column, and the flowthrough was 
collected for subsequent analysis. The column was extensively washed with 20 mM 
Na2HPO4, 150 mM NaCl (pH 7.2), and the antibodies bound to the column were eluted by 
0.1M glycine buffer (pH 2.8) (0.5 ml/fraction), immediately neutralized with 50 µl Tris 1M 
(pH 8.0), and dialyzed overnight against PBS. The anti-viral deiminated peptides antibody 
content in the eluates and flowthrough was tested by ELISA. 
 
Competition assays 
For the competition assays, the amount of anti-viral deiminated peptides antibodies that 
yielded 50% of maximum binding to the solid phase was determined. This amount of 
antibodies diluted in PBSBT was then preincubated with the synthetic peptides for 30 minutes 
at 37°C before being transferred to the antigen-coated plates. Thereafter, ELISAs were carried 
out in a manner similar to that for direct binding. MAP viral derived peptide in the 
undeiminated form was used as the negative control, and the same peptide as the one coupled 
to the plate was used as the positive control. 
 
ELISA for anti-viral deiminated peptide IgG, IgM, IgA antibodies detection.  
Anti-deiminated viral peptides antibodies of different isotypes were detected by ELISA as 
previously described [19]. 
ELISA plates were coated with the citrullinated viral peptide synthesised as MAP, in which 
all the arginine residues are substituted with citrulline. Results are expressed as the percentage 
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of an internal positive sample; positivity threshold of the test (higher than the 95th percentile 
of healthy controls) is 15% for IgG, 20% for IgM and 15% for IgA. 
 
Statistical analysis.  
ANOVA (analysis of variance), Bonferroni post-hoc, Chi-square test, Fisher exact, Spearman 
rank correlation coefficient and Mann–Whitney tests were used. 
P<0.05 was considered as significative. 
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RESULTS 
 
Data obtained in our lab [and already published, see ref. 8] showed that using EBNA I35-58 
deiminated in vitro, anti-citrulline antibodies were revealed in 54% of RA sera, while using 
the synthetic citrullinated peptide EBNA I35-58  the percentage decreased to 45%. 
This observation leads to the hypothesis that the in vitro deiminated peptide is in fact a 
mixture of different forms of the same peptide with a different grade of citrullination and 
consequently different grade of antigenicity. 
To define the aminoacids critical for reactivity, we synthesised six peptide variants 
corresponding to EBNA I35-58 in which one arginine was substituted with one citrulline, 
according to the following scheme: 
 
 
EBNA I cit53   EBNA I35-58  Arg53->Cit 
EBNA I cit49   EBNA I35-58  Arg49->Cit 
EBNA I cit47   EBNA I35-58  Arg47->Cit 
EBNA I cit45   EBNA I35-58  Arg45->Cit 
EBNA I cit43   EBNA I35-58  Arg43->Cit 
EBNA I cit41   EBNA I35-58  Arg41->Cit 
 
 
We then analysed 35 RA sera and 12 NHS sera on citrullinated peptides in ELISA. As shown 
in  
Figure 1, none of the peptides allows a statistically significant discrimination between RA and 
NHS sera.  
 
However, a slightly difference in reactivity between the two populations is observed using 
peptide EBNA I cit47. 
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Figure  1.  Analysis of the reactivity of RA and NHS sera with different mono-citrullinated viral 
peptides. None of the peptides is able to discriminate between patients and controls. 
 
 
On the basis of this suggestion, we next synthesised two linear peptides corresponding to 
EBNA I35-58 with two Arginine Citrulline substitutions and compared the reactivity of 40 
RA sera towards these peptides, the EBNA I cit47 and the EBNA I35-58 completely 
citrullinated. 
 
 
EBNA I cit47    EBNA I35-58  Arg47->Cit 
EBNA I cit45-47   EBNA I35-58  Arg45,47->Cit  
EBNA I cit47-49   EBNA I35-58  Arg47,49->Cit 
EBNA I Cit   EBNA I35-58 R41+43+45+47+49+53→Cit 
 
 
We found that the percentage of RA positive sera increases proportionally to the number of 
arginine citrulline substitution (28% EBNA I cit47, 31% EBNA I cit45-47, 35% EBNA I cit47-
49, 43% EBNA I Cit), reaching higher values when all the arginine were substituted to 
citrulline. The reactivity of NHS remained the same. 
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Figure 2. Reactivity of RA and NHS sera with EBNA I35-58 derived mono and di-citrullinated 
peptides. 
 
 
These results lead us to focus our attention on totally citrullinated sequences. 
 
It is already known that ACPA recognise preferentially citrulline flanked by small and neutral 
aminoacids like glycine, serine, or threonine, for such a reason called “permissive”. 
Bioinformatic analysis of sequence databases for Epstein Barr Virus proteins 
(http://www.expasy.ch/sprot) showed that sequences where arginine are flanked by neutral 
and small aminoacids, thus potentially deiminable and recognisable, are present in other 
portions of Epstein Barr Virus proteins, namely EBNA 1, EBNA 3, EBNA 4, EBNA 6, LMP1 
and LMP2, all proteins expressed during the latency phase of viral cycle (see Chapter 5). 
Linear peptides corresponding to some of these sequences were synthesised with all the 
arginines substituted with citrulline. 
A first analysis carried out on a small number of sera showed that EBNA I derived deiminated 
peptides different from the sequence aa. 35-58 do not discriminate between RA and NHS. On 
the contrary, a peptide derived from another Epstein Barr Virus Nuclear Antigen (and defined 
as linear deiminated viral peptide) in its citrullinated form allows differentiation between RA 
and normal subjects (Figure 3; p<0.001). 
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Figure 3. Reactivity of NHS and RA sera with the linear deiminated viral peptide (linear DVP). 
Results are expressed as the percentage of positivity of an internal positive control defined as 100%. 
 
 
 
To validate the potential use of this linear deiminated viral peptide (linear DVP) as antigen to 
detect ACPA, a second analysis with 123 RA (102 anti-VCP- and 21 Anti-VCP+) and 41 
NHS was performed on the linear peptide. The cut off value was set up at the 95° percentile 
of the control population. 
We found that 32.5 % of RA sera react with the linear DVP, when compared with 7% of 
control sera. Subdividing the population of RA patients among anti-VCP+ and anti-VCP-, we 
found that 50% of anti-VCP+ and 30% of anti-VCP- RA sera react with linear DVP, thus 
suggesting that anti-VCP and anti-linear DVP antibodies are partially overlapped populations 
belonging to the family of ACPA (Figure 4). 
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Figure 4. Reactivity of RA sera (anti-VCP+ and anti-VCP-) and NHS with linear DVP.  
Results are expressed as the percentage of positivity of an internal positive control defined as 100%. 
 
 
 
 
On the basis of these interesting results, the linear deiminated viral peptide has been 
synthesised as MAP.  
 
ELISA were performed on 117 sera from RA unselected patients, 89 from healthy subjects 
and 162 from control diseases, employing the MAP deiminated viral peptide (MAP-DVP) as 
coating agent. 
Setting the threshold value at the 95° percentile of the normal population, we found anti-
deiminated viral peptide in 55% of RA sera where compared with less than 5% of controls 
(Table 2) [Pratesi F. et al. Submitted]. 
 
 
 
 
 
 
P< 0.001 
P<0.001 
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Disease Anti-VCP Anti-DVP 
Rheumatoid arthritis 46/94 (49%) 57/94 (60%) 
Early arthritis 2/9 (22%) 2/9 (22%) 
Systemic lupus erythematosus 0/29 (0%) 0/29 (0%) 
Sjogren Syndrome 0/13 (0%) 1/13 (7%) 
Systemic sclerosis 1/21 (4.7%) 1/21 (4.7%) 
Mixed cryoglobulinemia 1/21 (4.7%) 1/21 (4.7%) 
Infectious mononucleosis 1/26 (3.8%) 2/26 (7.7%) 
Undifferentiated arthritis 0/20 (0%) 3/20 (15%) 
Rheumatic polymialgia 1/33 (3%) 3/33 (9%) 
Ankylosing spondilitis 2/15 (13,3%) 1/15 (6.7%) 
 
Table 2. Percentage of positive sera for anti-VCP and anti-DVP antibodies  in rheumatoid arthritis, 
control diseases and healthy controls 
 
These results suggested that anti-DVP assay is more sensitive than anti-VCP assay. 
Comparing the two assays by Receiving Operating Characteristic curve (ROC curve) analysis, 
the better sensitivity of anti-DVP assay in the evaluation of anti-citrullinated peptide 
antibodies with respect to anti-VCP assay was confirmed (Figure 5). The area under the curve 
(AUC) represent a measurment of the accuracy of the test and is classified traditionally 
according to this system: 
AUC = 0.9 – 1.0 excellent 
AUC = 0.8 - 0.9  good 
AUC = 0.7 - 0.8 fair 
AUC = 0.6 - 0.7 poor 
AUC = 0.5 - 0.6  fail 
 
 
 
 
 
 
 
 
 
 
Figure 5. ROC curve analysis of anti-VCP and anti-DVP assays 
AUC:0,92 AUC: 0.8 
Anti-DVP Ab Anti-VCP Ab 
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In the same RA population we measured anti-CCP antibodies and we compared the results of 
anti-CCP, anti-VCP and anti-DVP antibodies (Figure 6). 
We found that the levels of antibodies detected by the three assays are strongly correlated, 
thus suggesting that CCP, VCP and DVP are substrates equally able to reveal antibodies 
belonging to the ACPA family. 
An interesting finding was that RA sera are present that recognise only a citrullinated peptide 
and not the others, thus suggesting an heterogeneity in the immune response and that ACPA is 
a family of overlapping but distinct antibody populations. 
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           Figure 6. Correlation among anti-VCP, anti-DVP and anti-CCP antibodies in RA patients.  
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The affinity of anti-DVP antibodies has been analysed by liquid phase inhibition assay. 
Preincubation of anti-DVP antibodies with DVP inhibited the binding  
When incubated in liquid phase DVP, VCP and GC inhibited the binding of anti-DVP 
antibodies to DVP on the solid phase. However a different rate of inhibition has been 
observed from a patient to another. In fact in one case the rate of inhibition of DVP, VCP was 
almost the same (Figure 7b) with MAP GC showing a slightly lower inhibition ability (Figure 
7a. In another case DVP showed an higher inhibition ability than VCP and MAP-GC (Figure 
7b) [Pratesi F et al. Submitted]. 
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Figure 7a. Inhibition of binding of anti deiminated viral peptide (anti-DVP) antibodies to DVP 
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Figure 7b. Inhibition of binding of anti deiminated viral peptide (anti-DVP) antibodies to DVP 
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The data so far reported were obtained measuring antibodies of IgG isotype, but 
autoantibodies of other isotypes may as well be present in autoimmune sera. Thus, we 
measured anti-DVP of IgG, IgM and IgA isotype in 100 normal sera, 107 RA and 196 disease 
controls. 
 
Setting the threshold value at the 95° percentile of the normal population, IgG anti DVP were 
found in 65%; IgM anti DVP in 44%; and IgA anti-DVP in 48% of RA patients (Figure 8) 
[Pratesi F. et al. Submitted]. 
 
Analysing these data by Mann Whitney assay, anti-DVP of IgG and IgM and IgA 
differentiated RA from normal subjects and disease controls (P<0.0001 for IgG, P<0.001 for 
IgM, P<0.05 for IgA).  
Anti-DVP IgM discriminate RA from Sjogren syndrome, but with a lower strength with 
respect to the other diseases (P<0.05).  
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Among RA patients, 10 were single positive for IgG anti-DVP, 5 for IgA and 2 for IgM. Six 
patients were double positive for IgG and IgA, 0 for IgG and IgM, and 2 for IgA and IgM. In 
42 RA patients, IgG, IgA and IgM anti-DVP antibodies were detected (Figure 9).  
IgG + - - + + - + - 
IgM - + - + - + + - 
IgA - - + - + + + - 
 
Figure 9. Anti-DVP isotype distribution in RA patients. 
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DISCUSSION 
 
On the whole, our results, and mainly the differences in reactivity towards viral citrullinated 
peptides (e.g RA sera that are antiVCP+/DVP- or anti-VCP-/DVP+) and the differences in 
isotype usage (sera positive for IgM and/or IgA anti viral citrullinated peptides antibodies in 
absence of IgG), indicate a high interindividual variability in the response to citrullinated 
antigens. 
Recently, the heterogeneity of ACPA has been outlined by Sebbag et al. [20] and by Veerport 
et al. [21]. 
Sebbag et al. [20] measured anti citrullinated fibrinogen antibodies by means of a panel of 
overlapping deiminated peptides covering a large part of the fibrin sequence. Even if two 
major epitopes were described on fibrin, recognized by many RA sera, they nonetheless found 
12 different reactivity profiles. 
Veerport et al. [21] measured anti-CCP of IgA and IgM isotype in CCP-IgG positive sera 
from patients affected by established RA or undifferentiated arthritis. A high proportion of 
RA sera positive for IgG anti-CCP antibodies, contained also IgA anti-CCP (62%) and IgM 
anti-CCP (61%); they found also that, in undifferentiated arthritis, the contemporary presence 
of anti-CCP antibodies of different isotypes is strongly predictive of an evolution towards RA.  
In our population we detected IgM and IgA anti-DVP in sera negative for anti-DVP IgG, 
suggestive of an indipendent production of each isotype. Moreover, the presence of anti-VCP 
and anti-DVP IgM antibodies in patients with longstanding RA suggested that B cells 
producing IgM ACPA are persistently expanded in RA. Follow-up studies will be helpful to 
establish whether or not their production is regulated independently of the IgG. 
 
As shown by the comparison of anti-VCP, anti-DVP and anti-CCP antibodies, tests that use 
different substrates are only partially overlapped, probably because of differences in epitope 
recognition.  
Analysing EBNA 1 mono- and di-citrullinated peptides, we observed that not all the 
citrullinated peptides were equally reactive with ACPA. This observation underlines the 
importance of surrounding aminoacyl residues other than citrulline in the formation of ACPA 
epitopes. 
Moreover, we found that the higher is the number of citrullyl residues within the peptide, the 
higher is the number of RA sera reacting with the peptides.  
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In accordance with our results, proteomic analysis previously showed that different 
citrullinated autoantigens can be differentially recognised by different ACPA positive samples 
and that spots containing highly citrullinated proteins displayed high reactivity [22]. 
 
The use of DVP instead of, or in addition to, VCP for the detection of ACPA in RA sera leads 
to an improvement in assay sensitivity, that increases from 55% to almost 70%. 
However in terms of sensitivity further improvement in the assays based on viral citrullinated 
peptides may be achieved. The ideal assay should have a sensitivity of 100%, but since RA is 
such a complex and heterogeneous condition, absolute sensitivity is  a goal that probably 
cannot be met. However, the accumulation of data on the immune response to citrullinated 
antigens allows to foresee further improvements in sensitivity. The antibody response to 
citrullinated epitopes is in fact strongly polyclonal. By increasing the number of citrullinated 
epitopes that are presented in the assays, it should be possible to increase their sensitivity. 
Better knowledge on the identity of the citrullinated candidate autoantigens could be helpful 
in designing such additional epitopes.  
In principle, it is also possible to use the candidate autoantigens described above, citrullinated 
fibrin(ogen) and citrullinated vimentin, as antigens in diagnostic assays.  
The use of entire proteins does, however, pose some major problem. First of all, it is difficult 
to prepare sufficient amounts of high quality antigen and to control the degree of citrullination 
of these antigens. Another problem is the existence of circulating antibodies directed against 
the noncitrullinated protein. Because these antibodies are not directed against the citrulline 
moiety, they are not specific for RA and can therefore lead to false positives.  
The use of synthetic citrullinated peptides gives an absolute control over the exact epitopes 
presented. Orientation of the peptide in the plate can be defined using plates that allow 
covalent binding of the peptides via carboxy- or amino-terminal. Peptides that give false 
positive results (some peptides are reactive with sera even when citrulline is replaced by 
arginine, our unpublished observations) can be selectively left out. That is why an approach 
based on synthetic peptides as antigenic substrates should be preferred.  
Recent developments in microarray technology have opened up the possibility to measure 
reactivity against a large number of individual peptides at the same time. The main advantage 
of antigen-array technology is the ability to obtain multiplex autoantibody profiles with the 
ease of use and speed of a single ELISA. Sophisticated computer programs are needed to 
assess the presence of hundreds of autoantibody markers and to link each autoantibody profile 
to a certain diagnosis. This allows clinicians to obtain serological information useful for the 
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diagnosis of a wide variety of autoimmune diseases. Although this array technology looks 
very promising, it is still in its childhood and more studies are needed to confirm their validity 
in autoimmune disorders. 
 
In order to more precisely map the epitope recognised by anti DVP antibodies a series of 
inhibition assays was performed. 
The results of assays performed with anti-DVP antibodies purified from different RA patients 
are quite interesting. 
In fact, in one case incubation of anti-DVP antibodies, purified from an RA patient, with 40 
µg of either DVP or VCP led to the same rate of inhibition (80%), while preincubation with 
the same concentration of MAP GC peptide gave an inhibition of 45%. 
Preincubation of anti-DVP antibodies purified from another RA patient, with 40 µg of DVP 
led to an inhibition of 80%, whereas preincubation with the same concentrations of VCP and 
Map GC led to an inhibition rate of 50% and 25%, respectively. 
These results supported the heterogeneity of antibodies reactive with citrullinated epitopes in 
RA sera. The anti-DVP antibodies tested in these experiments are obviously of polyclonal 
nature; nonetheless the antibodies from the first patient probably reacted with epitopes 
completely shared by VCP and DVP and highly represented also in MAP GC. Antibodies 
purified from the second RA patient are, instead, directed against epitopes specific of DVP 
and to a lower extent with epitopes presented on VCP and MAP GC. 
A more precise characterisation of the epitopes recognised by anti-DVP antibodies using 
shorter citrullinated peptides is the objective of future studies. 
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CHAPTER 4 
 
 
GENETIC CONTROL OF ACPA PRODUCTION  
IN RHEUMATOID ARTHRITIS 
 
 
INTRODUCTION 
 
 
Rheumatoid Arthritis is a complex and heterogeneous disease in which multiple genetic and 
non-genetic factors interact over the time.  
Evidence of familial clustering was the first indication of a genetic susceptibility to RA. 
Using variance modelling, twin studies have determined that the RA heritability (that is the 
relative contribution of genetic variation to the liability of developing RA) has been estimated 
to be about 60% based on the higher monozygotic twins concordance rates (12–15%) 
compared to dizygotic twins (2–4%) [1]. Familial aggregation for RA, measured by the 
sibling recurrent risk ratio, vary from 2 to 17 depending upon the disease prevalence in the 
population used as reference [2]. Segregation analysis showed that the RA pattern of 
inheritance likely follows a mixed model, with a major gene (probably at the MHC) operating 
against a polygenic background [3]. The above findings indicate an important genetic 
component in RA. 
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HLA genetics of rheumatoid arthritis  
Several whole-genome scans for RA have been performed with multi-locus nonparametric 
linkage analysis to identify susceptibility loci (Figure 10). 
 
 
 
Figure 10. 
Whole genome scan results for rheumatoid arthritis. Chromosomal regions identified by whole 
genome scan linkage analysis (p<0.05) are indicated in yellow for Japanese population, green for UK 
population, red for European population and blue for North American population. Note that the MHC 
region (on chromosome 6) is the only one consistently linked to disease. 
 
 
The HLA region have been the only one with significant evidence of linkage (LOD score>3.6 
or P<3×10−5) across all the genome scans except the Japanese study. For RA the HLA 
complex contribution has been estimated to be about 30-35% [2] 
 
An association between genes located in the HLA region and the likelihood of developing RA 
was first suspected in 1976 by Stastny, who found RA to be associated with the mixed 
leukocyte culture type Dw4 (HLA-DRB1*0401) [4]. Further investigations have established 
more RA-associated alleles, mainly HLA-DRB1*0401, *0404 and *0408 in Caucasians; 
HLA-DRB1*0405 in Spaniards, Japanese and Jews, HLA-DRB1*0101/2 in Israelis, HLA-
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DRB1*1402 in some Native Americans such as Pima and Yakima Indians, and HLA-
DRB1*1001 in Greeks [5, 6]. In the late 1990s, when technical progresses in molecular 
biology allowed sequencing of the HLADRB1 locus, Gregersen put forward the shared 
epitope hypothesis to explain why the Class II region of the major histocompatibility complex 
(MHC) was associated with RA. According to this hypothesis, the HLA-DR antigens are 
directly involved in the pathophysiology of RA and the association between HLA-DR and RA 
is ascribable to susceptibility alleles that encode a homologous amino acid sequence in the 
third hypervariable region of the first domain of the HLA-DR beta chain [7]. This sequence, 
which extends from position 70 to position 74 on the amino acid chain (70QRRAA74 or 
70KRRAA74 or 70RRRAA74), is encoded by the DR4 (DRB1*0401, 0404, and 0405), DR1 
(DRB1*0101 and 0102), and DR10 (DRB1*1010) alleles and is associated with RA. 
 
 
 
The conserved motif ([Q/R]-[R/K]-R-A-A) constitutes an α-helical domain forming one side 
of the antigen binding site, a site likely to affect antigen presentation. Thus, the SE might 
selectively bind an arthritogenic peptide which could favour an autoimmune response. 
Negatively charged anchor residues best fit into this positive binding pocket 4, as in the case 
of the Collagen II peptide (261–263), an epitope in humantransgenic mouse models of RA 
[8]. HLA alleles with a negatively charged amino acid at any one of these positions are not 
associated with the disease. These alleles usually contain an aspartic acid (D) at residue 70 or 
the common motif 70DERAA74 (HLA-DRB1*0103, *0402, *1102, *1103, *1301, *1302, and 
*1304), and may protect against RA or favours a less erosive disease. 
In fact, in the middle of ninethy, Zanelli discovered that the DRB1 carrying 70DERAA74 
(alleles DRB1*0103, *0402, *1102, *1103, *1301, *1302) appeared to be associated with 
protection from RA [9]. He also extended the haplotype contributing to RA predisposition to 
DQ-DR alleles more than to DR alleles alone [10]. 
On the basis of these findings he proposed the RA protective (RAP) hypothesis, focused on 
two new aspects: 
• A new DRB1 shared epitope that is recognised as a peptide by Tregs 
• DQ molecules instead of DR molecules (that under any respect function in the same 
way as in the original SE hypothesis) are associated with RA. 
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While the DQ involvement in RA remained elusive, the association of DERAA positive 
DRB1 alleles with protection from RA (even in the presence of susceptibility alleles) has been 
confirmed by other studies [11]. 
Moreover, while HLA-DRB1 SE alleles have been described associated with severe course of 
the disease (in terms of bone destruction), DERAA  DRB1 alleles appeared to be associated 
also with protection against development of bone destruction [12]. 
 
Studies testing the SE hypothesis have rejected the idea that each SE allele confers the same 
risk [13, 14, 15, 16]. 
Apart from the associations of some SE negative DRB1 alleles with protection, the SE 
hypothesis could also not explain that the relative risks for RA varied considerably between 
different SE-carrying DRB1 alleles [17]. In fact this was one of the reasons why the RAP 
hypothesis was developed. 
The RAP hypothesis could however was unable by itself to explain the relationship between 
HLA and RA.  
Reviron et al. classified the SE-negative DRB1 alleles according to the electric charge of the 
P4 pocket and observed an association between negative or neutral charge and protection 
[18].  
In a study, Laivoranta-Nyman et al. compared different hypotheses regarding HLA-SE and 
concluded that ‘‘the effect of HLA class II region genes is more complicated than any of the 
existing hypotheses can explain’’. They confirmed gene dose effects both for susceptibility 
and protective alleles and haplotypes [19]. 
 
Recently, Tezenas du Montcel and coworkers proposed a model of the SE component in RA 
[20]. Those investigators reconsidered the SE hypothesis and generated a new classification of 
HLA-DRB1 alleles, based on their investigation using the MASC (Marker Association 
Segregation Chi 
Square) method, which was conducted in 100 trio families (one case and both parents) and 
132 index cases from affected sibling pair families, all from the French Caucasian population.  
They proposed that the risk for developing RA depends on whether the RAA sequence 
occupies positions 72–74 and, if this is the case, on the amino acids at positions 71 and 70. 
For those RAA alleles, lysine (K) at position 71 conferred the highest risk, arginine (R) an 
intermediate risk, and alanine (A) or glutamic acid (E) the lowest risk. Glutamine (Q) or 
arginine (R) at position 70 conferred greater risk than did aspartic acid (D). This resulted 
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initially in five allele groups, which were simplified to three allele groups defining six 
genotypes with different RA risks. This study was the first to model the HLA component in 
RA taking into account both association and linkage data, resulting in a reshaped SE 
hypothesis. 
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HLA-DRB1 amino acid sequence for alleles observed among rheumatoid arthritis patients and 
their classification according to du Montcel and collegues [20] 
HLA-DRB1 allele Aminoacid position Classification of  
du Montcel and collegues 
 69 70 71 72 73 74 75 76  
HLA-DRB1*0101 E Q R R A A V D S3P 
HLA-DRB1*0102 - Q R R A A - - S3P 
HLA-DRB1*0103 - D E R A A - - S1 
HLA-DRB1*03 - - K - G R - - X 
HLA-DRB1*0401 - Q K R A A - - S2 
HLA-DRB1*0402 - D E R A A - - S1 
HLA-DRB1*0403 - - - - - E - - X 
HLA-DRB1*0404 - Q R R A A - - S3P 
HLA-DRB1*0405 - Q R R A A - - S3P 
HLA-DRB1*0407 - - - - - E - - X 
HLA-DRB1*0408 - Q R R A A - - S3P 
HLA-DRB1*0411 - - - - - E - - X 
HLA-DRB1*07 - D - - G Q - - X 
HLA-DRB1*08 - D - - - L - - X 
HLA-DRB1*0901 - R - - - E - - X 
HLA-DRB1*1001 - Q R R A A - - S3P 
HLA-DRB1*1101 - D R R A A - - S3D 
HLA-DRB1*1102 - D E R A A - - S1 
HLA-DRB1*1103 - D E R A A - - S1 
HLA-DRB1*1104 - D R R A A - - S3D 
HLA-DRB1*12 - D R R A A - - S3D 
HLA-DRB1*1301 - D E R A A - - S1 
HLA-DRB1*1302 - D E R A A - - S1 
HLA-DRB1*1303 - D K R A A - - S2 
HLA-DRB1*1323 - D E R A A - - S1 
HLA-DRB1*1401 - R - - - E - - X 
HLA-DRB1*1402 - Q R R A A - - S3P 
HLA-DRB1*1404 - R - - - E - - X 
HLA-DRB1*15 - Q A R A A - - S1 
HLA-DRB1*16 - D R R A A - - S3D 
In the du Montcel and colleagues classification, the HLA–DRB1 alleles were first divided into two groups according to the 
presence or absence of the RAA sequence at positions 72–74, which denote S and X alleles (respectively shared epitope and 
nonshared epitope alleles). The S alleles were subsequently divided into four groups according to the two first amino acids at 
positions 70 and 71 (boldface): S1 for ARAA and ERAA, S2 for KRAA, S3 for RRAA (divided into S3P for QRRAA and S3D for 
DRRAA according to position 70), and X for all non-RAA motifs. The conventional classification of the amino acids was used, 
here divided into three biochemical subgroups, as follows: group 1 = G for glycine, A for alanine, V for valine, L for leucine 
(aliphatic amino acids (nonpolar hydrophobic)); group 2 = K for lysine, R for arginine (basic amino acids (polar and positively 
charged)); group 3 = E for glutamic acid, Q for glutamine (the amide corresponding to E), D for aspartic acid, and N for 
asparagines (the amide corresponding to D) (acidic amino acids and corresponding amides are very hydrophilic; acidic amino  
acids are polar and negatively charged at physiologic pH, amides are polar and uncharged, and not ionizable) [36 Gourraud] 
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Role for non HLA genes in the susceptibility to RA 
 
To increase accuracy of genome screens despite the large interval between markers, a linkage 
study was conducted in France using 1088 highly informative microsatellinte markers. This 
study confirmed the role of HLA locus and identified 19 non-HLA loci, located on 
chromosomes 1, 2, 3, 4, 5, 12, 13, 16, 18, 20, 22, and X. [21]. 
 
TNFR2 at 1p36 
Several genome screens identified 1p36 as a locus of interest for RA. [22]. This locus contains 
the TNFR2 gene encoding the TNFalpha receptor 2. The crucial role of TNFα in the 
pathophysiology of RA and the fact that the TNFR2 gene is present within a locus of interest 
indicate that this gene is a major candidate for RA. An SNP characterized by substitution of 
an arginine residue for the methionine residue at position 196 (exon 6) alters the intracellular 
transmission of signals generated when TNFα binds to TNFR2 [23]. A number of study 
showed an association of this polymorphism with RA but this was often restricted to familial 
RA. On the contrary several case control studies found no association between this exon 6 
polymorphism and RA. [rev in 24]. Considering all the results, the role of this polymorphism 
would remain modest, as it would be confined to familial forms of RA. 
 
 
PTPN22 at 1p13 
The minor allele of non synonymous SNP in the protein tyrosine phosphatase non receptor 22 
(PTPN22) gene located on chromosome 1p13, has been found to be associated with multiple 
autoimmune diseases. The PTPN22 gene is expressed in a variety of immunologically 
relevant tissues and encodes for the intracellular protein lymphoid tyrosine phosphatase 
(LYP). This protein play an essential role in intracellular signalling and is integral in the T 
cell receptor signalling pathway. An US group reported the association of the T allele of SNP 
R620W (1858T/C) which substitutes a tryptophan residue for an arginine residue, with RA 
susceptibility [25]. 
This was followed by numerous other studies in which the association with RA has been 
unequivocally confirmed in population of European descent, including UK, Finnish, Swedish, 
German, Dutch, Spanish and Canadian population [rev in 26]. 
This variant confers the second largest genetic risk to the development of RA, with an effect 
size of 1.8. The associated SNP results in a substitution of arginine (Arg620) to tryptophan 
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(Trp620) in one of the several proline rich motifs within the non catalytic C-terminal end of 
LYP.The Trp620 disrupt this motifs and results in increased catalytic activity of the enzyme 
with increased lymphocyte inhibition leading to an increased threshold level of stimulation 
required for T- and B-cell activation [25]. 
 
 
PADI4 at 1p36 
 
In RA, genome-wide linkage study of sibpairs conducted in 1998 by the European 
Consortium for Rheumatoid Arthritis Families (ECRAF) [22] demonstrated evidence of 
linkage in the 1p36 locus encompassing all the known PADI genes. 
 
Analyzing the SNPs located in the PADI4 gene in Japanese RA patients in a case control 
study (830 RA patients and 736 controls), Suzuki et al. reported that 8 SNPs in the pADI gene 
were associated with RA [27]. The stronger association was in the SNP padi4_94*T/C. In 
addition, a PADI4 haplotype defined by five exonic SNPs (padi4_89*A/G, padi4_90*T/C, 
padi4_92*G/C, padi4_94*T/C and padi4_104*T/C) was associated with RA. This 
susceptibility haplotype may play a finctional role by stabilising transcribed messenger RNAs 
and may be associated with the presence of ACPA. 
This study was replicated in an independent Japanese RA group [28] and similar results have 
been obtained in Korean patients [29], thus clearly establishing the role of PADI4 in 
conferring susceptibility to RA in patients of asian descent. 
On the contrary, controversial data have been obtained in caucasians: case-control studies did 
not confirm these findings in English caucasians [30], Spanish [31] and Swedish [32] patients. 
Similarly, a family-based association study in French caucasians reported negative findings 
[33].  
 
At variance with these findings, the North America Rheumatoid Arthritis Consortium [32] 
reported an association of a PADI4 allele with RA and a case-control study conducted in a 
French population reported an association between RA and the Japanese “susceptible” PADI4 
haplotype [34]. 
A metanalysis study was recently conducted taking into account 9 case-control studies 
(including some of the above cited) conducted in Japanese, Korean and Caucasians [35]. All 
together, these results indicate that PADI4 polymorphisms may represent a risk factor for RA, 
however playing a larger role in Asians than in Caucasians, where the data are conflicting. 
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HLA-SE and ACPA 
 
One of the main reason why RA is considered an autoimmune disease is the presence of 
autoantibodies 
The classical autoantibodies associated with RA are RF and ACPA. The detection of these 
two antibodies has similar (60-80%) sensitivity, both RF and ACPA may be present up to 
years before the onset of the disease and both are associated with severity of the disease. The 
specificity of RF and ACPA detection, on the contrary, differ widely, being estimated around 
60% for RF and over 95% for ACPA. 
 
Citrulline is a post-translational modification of arginine. In the presence of high calcium 
concentration (which, e.g., occurs when cells udergo apoptosis) the enzyme peptidyl arginine 
deiminase (PAD) which is present in the granulocytes and monocytes converts the positively 
charged iminogroup of arginine to the uncharged carbonyl group of citrulline. This may 
increase the peptide affinity for SE-positive DRB1 molecules [36] 
A number of studies have been performed to address the issue of the preferential association 
of the SE with ACPA-positive RA. 
A number of studies from the group of Huizinga and Toes in Leiden, performed by anti-CCP 
assay as method to detect ACPA, shed light on this issue, allowing to conclude that: 
• the SE epitope is exclusively associated with anti-CCP-positive RA and not at all with 
anti-CCP-negative RA. 
• the association of SE with RF is secondary to the association of SE with anti-CCP. 
• the DERAA protecting allele conferes the same degree of protection in anti-CCP-
positive RA and in anti-CCP-negative RA. 
 
Among HLA-DRB1 alleles, the one most strongly associated with anti-CCP antibodies is 
HLA-DRB1*0404: morever, patients with HLA-DRB1*0404 showed higher titers of anti-
CCP antibodies than patients with other RA associated HLA-DR alleles. 
This association is valid also when other substrate for ACPA detection are used. In fact, The 
RA-associated HLA–DRB1*0404 allele is also associated with production of antibodies to 
citrullinated fibrinogen. On the contrary, DRB1*0401 and DRB1*01 tend to be associated 
with anti–citrullinated fibrinogen antibodies, but this tendency is not statistically significant 
[37]. 
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Finally, a citrullinated peptide derived from vimentin has been observed to be bound by HLA-
DRB1*0401 and presented to T cells where induced proliferation [36].  
 
Recently, a genome wide association study of genetic predictors of ACPA level showed 
definitively that the most significant genome region affecting ACPA titers in RA is the MHC. 
The study, moreover, identified a SNP in moderate linkage disequilibrium with HLA-DR3, 
which may influence ACPA titer independently of the HLA-SE [38]. 
 
 
 
 
Gene-environment interactions in RA. The role of smoking, HLA-SE and 
ACPA. 
 
The data in the literature indicate that antibodies to autoantigens that have been modified by 
citrullination are beside their usefulness as diagnostic tool, may also contribute to arthritis. As 
citrullination is a common process in many physiological events, including apoptosis and 
inflammation, the rate-limiting steps appear to be whether and when immunity is triggered 
against these modified proteins and which epitopes of which proteins are being recognized. 
Most information on how genes and environmental determinants interact in increasing risk for 
ACPA-negative as well as ACPA-positive RA comes from case control studies in which 
population-based RA cohorts were compared with healthy individuals from the same 
population. The most striking finding from these studies overall is the dichotomy between 
ACPA-positive and ACPA-negative RA concerning both genetic and environmental 
determinants. 
Thus, as noted above, both the major genes, i.e., HLA-DRB1 SE and PTPN22 alleles that 
predispose for RA, were shown to be risk factors for ACPA-positive disease, but not for 
ACPA-negative disease.  
Recently, a striking gene-gene interaction was demonstrated between HLA-DRB1 SE alleles 
and the susceptibility allele of the PTPN22 gene, where the combination of two SE alleles and 
the 620W allele of PTPN22 increased the risk forACPA-positiveRA 20-fold compared to 
individuals with none of these genetic risk factors [39]. These data indicated that both 
molecular pathways involving MHC class II–dependent T cell activation and tyrosine 
phosphatase–mediated cell activation are of pathogenic importance in ACPA-positive RA. 
More recently, additional genetic determinants, notably one gene in the TRAF1-C5 region, 
have also been shown to associate with ACPA-positive RA [40], but not with ACPA-negative 
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disease [41]. Although the susceptibility gene(s) has not yet been definitely identified, its 
possible relation to TRAF1- or C5-mediated functions makes it an additional determinant 
influencing a pathway related to adaptive immunity and antibody-mediated effector functions. 
 
Smoking, long known to be the major environmental factor in increased risk for RA [42, 43], 
was recently demonstrated to be a significant influence on RF+ disease (Masdottir B, Jonsson 
T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarsson H. Smoking, rheumatoid factor 
isotypes and severity of rheumatoid arthritis. Rheumatology 2000;39:1202–5) and [44] and 
[45].  
Smoking used to be considered as an unspecific risk factor, of interest mainly from a public 
health perspective, rather than a reasonably well-defined trigger of RA, and studies of its 
actions could help elucidate the molecular pathology of RA. Our investigations showed a 
striking gene-environment interaction between smoking and the presence of the HLA-DRB1 
SE risk alleles as risk factors first for RF+ disease [46], and then even more pronounced for 
ACPA-positive RA (26). The relative risk of developing ACPA-positive RA was over 20 
times higher for smokers carrying two copies of the HLADRB1 SE alleles than for non 
smokers with no SE alleles. On the other hand, no increased risk was discerned for 
development of ACPA negative RA [47]. The studies described above provide one of the 
most striking examples of gene environment interaction in the risk of developing a specific 
diagnosis, where this risk is strictly confined to an immunologically defined subgroup of 
patients smoking is associated with an increased presence of citrullinated proteins in 
bronchoalveolar lavage (BAL) cells from healthy smokers and smokers with pulmonary 
inflammation [48]. Subsequently, we extended this study to demonstrate that this increased 
Citrullination may be due to increased expression of PADs, in particular PAD2 in BAL cells 
from smokers. We then proposed the following model for how immunity to citrullinated 
proteins might be triggered by smoking and how the gene environment interactions might be 
explained [48]. Smoking may cause PAD activation and subsequent citrullination in lungs, at 
the same time as components in smoke act as unspecific adjuvants activating APCs in the 
pulmonary compartment. In individuals carrying immune response genes that predispose to a 
strong immune reaction against certain citrullinated peptides, and where other genetic variants 
are also present (such as the PTPN22-coded tyrosine phosphatase), an immune response with 
antibody production to citrullinated proteins might be triggered.  
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PATIENTS AND METHODS 
 
 
Patients 
All subjects provided their informed consent, and the ethics committee of Hopital Bicetre 
(Kremlin-Bicetre, France) approved the study. 
Families with rheumatoid arthritis were recruited through a national media campaign followed 
by the selection of individuals who fulfilled the 1987 American College of Rheumatology 
(formerly the American Rheumatology Association) revised criteria for rheumatoid arthritis 
[49]. All clinical data were reviewed by a rheumatologist.  
One hundred seventy two white French RA patients coming from trio families were 
investigated. Trio families were composed of one affected subject and the two parents (with 
four white European grandparents). Among the 172 rheumatoid patients, 155 were women 
and 17 were men; their mean age at disease onset was 39.6 (± 9.3) years; mean (± standard 
deviation) disease duration, 8 (± 2.5) years. 
 
 
HLA-DRB1 genotyping 
Genomic DNA was extracted from ethylenediamine tetraacetic acid anticoagulated peripheral 
blood, using a standard proteinase K digestion and phenol/chloroform extraction method, in 
all patients at the time of inclusion. HLA-DRB1 genotyping was performed using the 
polymerase chain reaction-sequence specific primer (SSP) method using Dynal Classic SSP 
DR low resolution and the Dynal Classic high resolution SSP (Dynal Biotech, Lake Success, 
NY, USA) for subtyping of HLA-DRB1*01, *04, *11, *13 and *15 alleles. Sequencing of 
exon 2 of HLA-DRB1 was performed for all four HLA-DRB1*04 alleles, ambiguous with the 
Dynal Classic method. HLA-DRB1 allele frequencies of control genotypes (obtained by 
combining untransmitted parental alleles for each family) were similar between samples and 
were comparable to the allele frequencies reported for the French population in the 11th 
Histocompatibility Workshop [50]. 
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HLA-DRB1 allele classification 
HLA-DRB1 alleles were pooled according to the new classification proposed by du Montcel 
and colleagues [20] 
Briefly, the HLA-DRB1 alleles were first divided into two groups according to the presence 
or absence of the RAA sequence at positions 72–74 and were denoted S and X alleles, 
respectively. The S alleles were subsequently divided into four groups according to the amino 
acid at position 71: an alanine (A), a glutamic acid (E), a lysine (K), or an arginine (R). 
Different groups were thus defined in the new classification: S1 for ARAA and ERAA, S2 for 
KRAA, S3 for RRAA, and X for 
all non-RAA patterns. Since an aspartic acid (D) at position 70 was reported to be protective 
against RA susceptibility in comparison with a glutamine (Q) or an arginine (R) at the same 
position, two additional groups were defined: S3D for DRRAA, and S3P for QRRAA or 
RRRAA  (Table 1). 
 
 
Binding of anti–viral citrullinated peptides/proteins antibodies 
Anti peptide antibodies were detected in the sera by ELISA, as previously described [51, 52]. 
Briefly, the different peptides (either linear or MAP) were added to polystyrene plates (Nunc 
MaxiSorp F96; Nunc, Roskilde, Denmark) at 2-5 µg/ml in PBS and incubated overnight. 
Saturation was carried out with PBS containing 3% BSA for 45 minutes at room temperature. 
Sera diluted 1:200 in PBS containing 1% BSA and 0.05% Tween 20 (PBSBT) were incubated 
on the plates for 3 hours at room temperature. After washings with PBS–1% Tween and PBS, 
anti-human IgG alkaline phosphatase (Sigma) conjugated 1:3,000 in PBSBT was added to the 
wells, and the plates were incubated for 2 hours at room temperature. 
Alkaline phosphatase activity was revealed with p-nitrophenyl phosphate in 50 mM Na2CO3 
(pH 9.6). 
 
 
Peptide binding to HLA-DRB1 molecules 
Peptide-binding affinity to purified HLA-DRB1*0101, *0401, *0404, *0301, *0701, *0802, 
*1101, and *1302 molecules was determined relative to radiolabeled peptide probes as 
described previously. The nanomolar concentration of unlabelled vimentin peptide necessary 
for 50% inhibition of the labelled peptide to the purified HLA-DRB1 molecules (IC50) was 
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used as an approximation of the affinity of interaction (KD). Results are expressed as the 
inverse of the IC50 values measured in nanomolar concentration. 
 
 
Statistical analysis 
Agreements with Hardy–Weinberg equilibrium were tested using Pearson's chi-square test 
and Fischer's exact test when relevant. The association between the HLA-DRB1 gene 
polymorphism and anti-VCP and DVP antibodies was tested by comparing (by the chi-square 
test or the exact Fisher test when relevant) the distribution of positive or negative patients for 
anti viral citrullinated peptides antibodies among carriers and noncarriers for shared epitope 
alleles according to the classical classification, and for each of the four groups of HLA-DRB1 
alleles encoding the SE, defined according to the new classification of HLA-DRB1 alleles 
(S1D, S2D, S3P, S3D). Odds and odds ratios (95% confidence intervals) were also calculated. 
All P values were two-sided, and P < 0.05 was considered statistically significant. 
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RESULTS 
 
Demographic and immunologic characteristics of RA patients 
The main baseline demographic and immunologic characteristics of the 172 patients with RA 
included in the present study were the following: 155 women (90%) and 17 men (10%); mean 
(± standard deviation) age, 35 (± 9.3) years; mean (± standard deviation) disease duration, 8 
(± 2.5) years; number (%) anti-VCP1 antibody-positive 89/172 (51%); and number (%) anti-
VCP2 antibody-positive, 106/172 (61.6%). 
 
Allele frequencies for HLA-DRB1 polymorphisms 
The frequencies of HLA-DRB1 alleles, classified into five groups according to the new 
classification, were as follows: S1, 37/344 (10.8%); S2, 91/344 (26.5%); S3D, 33/344 (9.6%); 
S3P, 99/344 (28.8%); and X, 84/344 (24.4%). No departures from Hardy–Weinberg 
equilibrium were found for HLA-DRB1 alleles classified into the five groups (P = 0.7171; 10 
degrees of freedom). 
 
Relationship between HLA-DRB1 allele status and anti viral citrullinated peptides 
autoantibody status. 
Table 4 presents the status for anti-viral citrullinated antibodies among patients carrying the 
different HLA-DRB1 alleles encoding or not the SE classified into five groups according to 
the new classification [Pratesi F. et al., submitted].  
 
X carriers do not associate with anti-VCP and anti-DVP antibodies; they showed a lower 
frequency of anti viral peptides antibodies (odds ratio < 1) but not significative (p > 0.05), 
thus suggestive of a trend in protection for non SE alleles in term of autoantibodies 
production. 
Among SE encoding subgroups, S1 carriers showed a lower frequency of anti-VCP and anti-
DVP antibodies (odds ratio < 1) but not significative (p > 0.05).  
S3P and S3D do not showed any particular association with anti-viral peptide antibodies 
Anti-VCP and anti-DVP antibodies are associated with S2 alleles subgrouping.  
In fact, S2 carriers showed an higher frequency of anti-VCP antibodies and anti-DVP 
antibodies (odds ratio > 1 and p < 0.05). 
The 2 different S2 sequences [Q-K-RAA (*0401) and D-K-RAA (*1303)] has been  evaluated 
in terms of association with autoantibodies. HLA-DRB1*0401 showed association with either 
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anti-VCP or anti-DVP antibodies (odds ratio > 1 and p < 0.02), while HLA-DRB1*1303 did 
not showed any correlation with antibodies production, even if the number of RA patients 
carrying this allele is very small to draw a conclusion on the weight of this allele in the 
predisposition to ACPA production. 
 
It has been suggested that in anti-CCP–positive patients, the presence of SE alleles is 
associated with higher levels of anti-CCP antibodies, and that the presence of 1 or 2 SE alleles 
does not result in an apparent difference in anti-CCP antibody level [53]. This observation is 
compatible with the notion that the SE alleles function as immune response genes in the 
development of anti-CCP antibodies. 
Thus, we wished to investigate whether anti-VCP and anti-DVP antibodies levels showed the 
same behaviour with respect to SE alleles of other ACPAs. To this end, the correlation 
between the presence of the SE alleles and the level of anti-VCP and anti-DVP antibodies was 
assessed. 
 
As shown in Table 3, we found that patients with at least 1 SE allele showed higher level 
either of anti-VCP or anti-DVP antibodies and that there are no statistically relevant 
differences between patients with 1 allele or two alleles. 
We refined the analysis to the S2 subgroup, the one strictly associated with anti-VCP and 
anti-DVP antibodies production. 
In this case we found no differences in the levels of anti-VCP and anti-DVP antibodies among 
the three groups (no S2, 1 S2 allele, and 2 S2 alleles) [Pratesi F. et al, submitted] 
 
 
 Mean (% positività) 
 No SE 1 SE 2 SE 
Anti-VCP 14,89 31,46 47,80 
Anti-DVP 17,50 47,80 54,68 
 No S2 1 S2 2 S2 
Anti-VCP 28,05 40,87 46,53 
Anti-DVP 43,11 59,72 63,39 
 
Table 3. Levels of anti-VCP and anti-DVP antibodies (expressed as % of positivity of an internal 
control) in RA patients stratified according to the absence of SE alleles or the presence of 1 or 2 SE 
alleles.  
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Relationship between HLA-DRB1 allele carrier status and anti viral citrullinated peptides 
autoantibody status in patients with rheumatoid arthritis 
  Carrier status OR CI95% Fisher Exact Test 
  Yes No    
S1 carrier 
      
pos 12 66 
VCP 
neg 22 72 
0.595 0.27-1.29 0.24 
pos 20 85 
DVP 
neg 14 53 
0.890 0.41-1.91 0.84 
      
S2 carrier 
      
pos 50 39 
VCP 
neg 30 53 
2.265 1.22-4.18 < 0.01 
pos 57 49 
DVP 
neg 23 43 
2.178 1.15-4.10 < 0.01 
       
S3P carrier 
      
pos 43 35 
VCP 
neg 50 44 
1.083 0.59-1.97 0.87 
pos 56 50 
DVP 
neg 37 29 
0.872 0.47-1.62 0.75 
       
S3D carrier 
      
pos 13 65 
VCP 
neg 18 76 
0.844 0.38-1.85 0.69 
pos 19 86 
DVP 
neg 12 59 
1.012 0.45-2.24 1 
       
X carrier 
      
pos 35 59 
VCP 
neg 40 38 
0.563 0.30-1.03 0.08 
pos 43 64 
DVP 
neg 33 32 
0.651 0.35-1.21 0.20 
Table 4. Data presented as n. Status for anti viral citrullinated peptides (anti-VCP and anti-DVP) 
antibodies among 172 patients with  rheumatoid arthritis, carrying the different HLA-DRB1 alleles 
encoding the shared epitope classified into four groups according to the new classification. Odds 
ratios, 95% alpha-risk confidence interval and P value for exact Fisher test. 
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Binding of citrullinated viral peptides to HLA-SE positive molecules 
We have tested the peptides for their capacity to bind various HLA-DR molecules. We tested 
each peptide for binding to DR1 (DRB1*0101), DR4w4 (DRB1*0401), DR4w15 
(DRB1*0405), DR7 (DRB1*0701), DR5w11 (DRB1*1101), DR6w19 (DRB1*1302), 
DR2w2 B1 (DRB1*1501), and DR2w2 B2 (DRB5*0101). In no instance did we find that any 
of the peptides bound any of the DR molecules at the highest dose tested (>10000nM) [Pratesi 
F. et al, submitted] 
The DVP did bind DR1 (DRB1*0101) with an very weak affinity (6180 nM). 
 
 84
DISCUSSION 
 
The results of the present study partially confirm previous evidences of an association 
between HLA-DRB1 gene polymorphism and autoantibody production in RA patients. 
An association between HLA-DRB1*01, HLA-DRB1*04 or HLA-DRB1*SE+ alleles and 
ACPAs was more constantly reported in European or North American RA patients [35]. 
In this work, we found only a trend in association between either anti VCP and HLA DRB1 
SE or anti-DVP and HLA DRB1 SE alleles (odds ratio > 1), without reaching the complete 
significance (Fisher exact test, p>0.05). 
However, subgrouping RA patients according to the new classification by du Montcef et al. 
[20], we observed a clear association between S2 alleles and anti viral citrullinated peptides 
antibodies. 
The S2 subgroup is comprised of HLA DRB1*0401 and HLA DRB1*1303. We found a 
strong association between antibodies to citrullinated viral peptides and HLA DRB1*0401, 
while no conclusions can be drawn from HLA DRB1*1303 analysis given the small number 
of SE*1303 positive RA patients. 
Most of the previous studies, based on the common classification, identified HLA-
DRB1*101, HLA-DRB1*0401, HLA-DRB1*404 and HLA-DRB1*1001 as predisposing 
alleles for ACPA production in RA, with a significant dose effect in patients carrying two of 
these predisposing alleles [rev. in 54]. Only a few association studies reported an HLADRB1 
allelic protective effect for ACPA production in RA. In these studies, HLA-DRB1*03 was 
associated with ACPA negative RA and decreased titers of ACPAs, even in the presence of a 
SE allele. In the new classification of HLADB1 alleles, HLA-DRB1*03 is not taken into 
account separately since it is classified into the X group of alleles, which do not encode the 
SE sequence. In the present study, complementary analysis did not show any association 
between HLADRB1*03 carrier status and RF or ACPA production (data not shown). The use 
of the classification by du Montcel and colleagues suggests a risk hierarchy in ACPA 
production in early RA patients: the S2 (KRAA at positions 71–74) and S3P (QRRAA or 
RRRAA at positions 70–74) alleles confer predisposition, while the S1 (ARAA or ERAA at 
positions 71–74) and S3D (DRRAA at positions 70–74) alleles confer pro-tection, in 
comparison with X (non-RAA patterns at positions 72–74). 
The results of this study partially confirm this tendency: in fact, the S2 alleles confer 
predisposition to anti-viral citrullinated peptides antibodies production and S1D and X alleles 
showed a tendency to confer protection. 
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To get a complete picture of the role of HLA in antibody production in RA, the results of 
genetic association should be taken into account together with the results of the binding of 
citrullinated viral peptides to HLA molecules. 
This work done in collaboration with the group of Alessandro Sette, University of California, 
showed that no significant binding is observed to any of the HLA DRB1 molecule analysed. 
 
It has been proposed that RA-associated HLA-DR alleles, whose peptide biding groove has a 
very basic P4 pocket, could bind citrullinated peptides better than native peptides. This 
hypothesis is supported by the fact that arginine-to-citrulline substitution results in the loss of 
a positive charge and by the demonstration that such a substitution in a single vimentin-
derived peptide allowed high affinity peptide interaction. However, data from the present 
study suggested that even high citrullination (i.e. high loss of positive charges) is not by itself 
sufficient for HLA interaction, even in the presence of genetic association. 
The weak genetic association among HLA SE and autoantibody production and the absence 
of binding to HLA molecule may suggest that viral citrullinated peptides are not presented by 
HLA to T cells. 
 
Thus, the hypothesis that HLA-SE alleles act as classic immune response genes in the ACPA 
response may be reconsidered. 
Under this respect, it is of interest that despite many efforts human T cells specific for 
citrullinated peptides have never been detected in RA patients. Such a negative result may be 
due to technical limitations, due to the low frequency of these cells in circulation or in 
inflammatory infiltrates, but it may also suggest that, in case T cells are really involved in 
ACPA production, the epitopes they recognize may not be citrullinated. The SE influence on 
disease severity and not only on disease susceptibility is also hard to reconcile with a mere 
HLA function in antigen presentation. 
Moreover, a promiscuous association of HLA SE with other diseases has bee reported (ref?), 
further stressing a more complex role of these alleles. 
Taken together, all these observations argue against the hypothesis of antigen presentation as 
the sole basis for RA-HLA association. 
 
An alternative hypothesis is that rather than emanating from the antigen presentation function 
of the HLA-DRB molecules, the RA-SE association is the result of linkage disequilibrium 
with other genes. This mechanism has been convincingly implicated in another MHC linked 
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diseases, hereditary hemochromatosis. In RA, however, this mechanism appears to be less 
likely, since it fails to explain the seemingly random occurrence of RA among genetically 
susceptible individuals, best illustrated by the low concordance rate of RA in monozygotic 
twins. 
An alternative hypothesis  proposed by the group of Holoshitz postulates that the SE acts as 
an allele-specific ligand that triggers NO-mediated signalling events in opposite cells [55]. 
In its native conformation, the SE occupies approximately  1.5 alpha-helical loops in the 
DRbeta1 domain and builds the lateral wall of the fourth pocket of the peptide binding 
groove. It is therefore legitimate to wonder whether an interaction between SE and a putative 
receptor in opposite cells is possible. The SE is part of the “sidewall” of the peptide groove 
and does not play a major role in peptide anchoring, a function that is primarily mediated by 
the “floor residues” of the groove. Among the five aminoacids of the SE, only one (K/R 71) 
has been shown to interact with some presented peptides. The other residues interact with 
outside molecules, such as the TCR, or merely help in maintaining the SE alpha-helical 
structure. 
Thus, the SE represents a relatively free subdomain, which, depending on the level of 
antigenic peptide occupancy and the nature of the lodged peptide, could allow sufficient room 
for interaction with other molecules. According to this hypothesis SE residues might also act 
as costimulatory signals, either linked to cognate peptide or not. 
 
Finally, the most represented aminoacid in the SE sequences is arginine. In the attempt to 
speculate about other roles of SE in RA pathogenesis, we can hypothesize that the SE by itself 
may contain citrulline residues originated by arginine modification during inflammatory 
events. 
The citrullinated SE sequences might together with other stimuli, directly activate anergic B 
cells specific to citrullinated antigens leading to antibody production or might induce 
progression of specific immature B cells towards plasmacells secreting antibodies to 
citrullinated antigen. 
This “B-centric” hypothesis may explain why T cells specific for citrullinated antigens have 
not yet been found and why HLA-DRB1 molecules do not bind all the citrullinated antigens. 
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CHAPTER 5 
 
EPSTEIN BARR VIRUS AND RHEUMATOID ARHTRITIS 
 
 
INTRODUCTION 
 
Rheumatoid arthritis is one of the most common autoimmune disorders with a 1% worldwide 
prevalence. RA leads to the destruction of synovial joints and to systemic manifestations. Its 
cause is so far unknown. However, both genetic and environmental factors are supposed to 
contribute to RA susceptibility. Among environmental factors, numerous infective agents 
have been suspected: Epstein Barr virus is the most interesting. 
 
 
Epstein Barr Virus (EBV) 
The Epstein Barr virus (or human herpesvirus 4) is a 172 kb double stranded DNA virus. 
EBV is carried lifelong; it causes infectious mononulceosis and has been linked to the 
development of several tumors, including Burkitt’s lymphoma, Hodgkin’s disease  and 
nasopharyngeal carcinoma and post-transplant lymphoproliferative disease. In most people 
primary infection and lifelong persistence are asymptomatic. [1]. 
EBV infects B lymphocytes or epithelial cell of the oropharynx [2]. To penetrate the cells, 
the EBV envelope glycoprotein gp350/220 binds to CD21 (type 2 complement receptor – 
C3d) on the cell surface. EBV then activates resting B cells. EBV-infected B cells begin to 
proliferate. Outgrowth of EBV-transformed B cells is controlled by EBV-specific cytotoxic 
T lymphocytes. EBV establishes a so-called “latent infection” in memory B cells. About 106 
B cells harbor the viral genome as an episome whose replicative cycle genes are inactive. 
Thus, no virions are produced. At this stage latent cycle genes produces a limit set of EBV 
proteins: Epstein Barr Nuclear Antigens (from EBNA 1 to EBNA 6), latent membrane 
antigen (LMA) and terminal protein (TP). The virus reactivates occasionally, switching from 
latent to the lytic cycle, during which transactivating proteins, structural viral proteins and 
envelope glycoproteins are produced. The antigens typical for the lytic phase include the 
viral capside antigen (VCA), early antigens (EA) and membrane antigen (MA) [3, 4]. The 
humoral response leads to the production of antibodies against viral proteins. The lytic and 
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the latent cycles each has a distinctive serological profile: antibodies to EA, VCA and 
envelope antigen are produced during early phases of infection. Anti-MA antibodies target 
the gp350 and stop the dissemination of the virus. Antibodies to EBNAs develop later on 
and persist throughout life. 
 
Epstein Barr Virus and Rheumatoid arthritis 
EBV infects almost the entire world adult population and for the past 25 years, a potential role 
of EBV in the pathogenesis of RA has been suspected. First, Alspaugh et al. [5] reported that 
sera from RA patients contained high titers of antibodies against a nuclear antigen present in 
EBV-infected cells. They later confirmed that sera from patients with RA contained high titer 
antibodies to latent and replicative EBV antigens like Epstein–Barr nuclear antigen (EBNA), 
viral capsid antigen (VCA), and early antigen (EA) [6]. Similarly, high titer antibodies to 
CMV were found in some RA patients. For both EBV and CMV, antibody titers in matched 
synovial fluids were lower than in sera, which did not suggest production of antibodies in the 
synovium [7]. 
Investigation of several T-cell functions in RA patients revealed defective suppressor T-cell 
function limited to EBV. In short, it takes more RA patient’s than control’s T cells to inhibit 
the outgrowth of EBV-infected B cells in vitro [8]. Furthermore, RA patients have more 
EBV-infected B cells than normal controls in their peripheral blood. Indeed, the mean 
frequency of spontaneously transforming B cells is five times higher in RA patients than in 
controls, although frequencies of B cell transformation in presence of exogenous EBV are 
similar in RA patients and normal controls [9]. 
The QKRAA amino acid sequence of HLADRB1* 0401, which carries disease susceptibility 
to develop RA, is also found on the EBV glycoprotein gp110. EBV gp110, encoded by the 
BALF4 open reading frame, is a major replicative antigen implicated in the control of 
infection [10]. It is expressed on the surface of lymphoblastoid cell lines and on the envelope 
of the budding virion during EBV replication [11]. Healthy individuals with prior EBV 
infection have serum antibodies to gp110 and their T cells recognize peptides containing the 
QKRAA motif. 
Gp110-specific T cell precursor frequencies in healthy controls are influenced by the HLA-
DR alleles they express. HLA-DRB1*07, an RA-protective allele, is associated with high 
frequencies of T cells specific for gp110 [11]. Strikingly, HLA-DR7 is also associated with 
high T cell responses to the gB glycoprotein of CMV [12]. gB proteins, the equivalent of 
EBV gp110 in other herpesviruses, are targets for both T cells and antibodies whose 
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recognition allows control of infection. Conversely, HLA-DRB1*0404, an RA predisposing 
allele is associated with low responses to gp110. In RA patients, disease severity is associated 
with low T cell responses to EBV gp110 [13]. 
Two EBV replicative phase proteins, BZLF1 and BMLF1, play a key role in controlling virus 
spreading. 
They are targets for cytotoxic T cells present in synovial fluids and synovial membranes of 
RA patients. These EBV-specific T cells recruited in the synovium may contribute to synovial 
inflammation observed in chronic RA [14]. 
In RA patients, poor control of EBV replication could result in higher EBV load. In the past, 
many techniques have been used to detect EBV in biological specimens, and negative results 
may reflect lack of sensitivity rather than absence of virus. 
Immunochemistry did not allow to detect EBV proteins in the synovial tissue or peripheral 
blood of RA patients [15]. In situ hybridization allowed to detect EBV-encoded RNAs 
(EBERs) in B lymphocytes from synovial tissue from RA but not osteoarthritis patients [16]. 
Semi-quantitative PCR techniques have been extensively used to amplify EBV and other 
viruses (CMV, HHV1-2-6). With these techniques, EBV DNA is detected more frequently in 
PBMCs, synovial fluid and saliva from RA than from controls and patients with other 
arthritides [17,  18, 19, 20. 21, 22]. 
More recently, using an accurate EBV DNA quantitation assay by real time PCR, it was 
shown that the EBV DNA content in PBMCs from patients with RA is 10-fold higher than 
that in PBMCs from healthy individuals or from patients with other inflammatory arthritides 
[23] 
 
 
EBV persists indefinitely in host B cells and encodes at least two proteins that interfere with 
apoptosis, namely BHFR1 (a viral homologue of the antiapoptotic protein Bcl-2) [24] and 
LMP-1 (latent membrane protein-1) [25]. 
However, during the course of EBV infection, a transient episode of acute neutropenia is 
frequently observed in most patients suffering from infectious mononucleosis (IM) [rev. in 
26] and although the molecular mechanisms underlying this condition are still unknown, 
apoptosis might represent a plausible explanation for such a depletion of circulating 
neutrophils. As a matter of fact, it has been observed that EBV particles could bind to 
neutrophils although these cells do not express CD21 [27] and that in vitro EBV infection 
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dramatically increases the rate of apoptosis: 77% of neutrophils are apoptotic after 20 hours 
post-infection, compared to 20% in uninfected cells [28]. 
 
 
It is known that calcium ions are required for activation of PAD enzymes, but the cytosolic 
calcium concentrations in normal cells is much lower (10-7 M) than the threshold Ca 
concentration for PAD activity (10-7 in normal cells versus (10-5 M). When cells are dying, 
PAD enzymes, either because of their leakage from cells or because of release of calcium 
from intracellular stores, become activated since the Ca concentration can be up to 10-3 M. 
Since neutrophils are very abundant in joints of RA patients where they partecipate to the 
pathogenesis of the disease, we examined the possibility that EBV transient infection of 
neutrophils could induce cell death and the consequent activation of PAD and protein 
deimination. 
Such a mechanism could initiate or perpetuate the rheumatoid arthritis cycle. 
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PATIENTS AND METHODS 
 
Purification of anti-VCP antibodies 
Viral citrullinated peptide was conjugated to CNBr-activated Sepharose (Sigma) according to 
standard procedures. Total immunoglobulins from RA sera containing high titers of anti-VCP 
antibodies were precipitated with 50% saturated ammonium sulfate; the precipitates were 
dissolved in phosphate buffer (pH 7.4) and dialyzed overnight against phosphate buffered 
saline (PBS). 
Enriched immunoglobulin preparations were applied to the column, and the flowthrough was 
collected for subsequent analysis. The column was extensively washed with 20 mM 
Na2HPO4, 150 mM NaCl (pH 7.2), and the antibodies bound to the column were eluted by 
0.1M glycine buffer (pH 2.8) (0.5 ml/fraction), immediately neutralized with 50 µl Tris 1M 
(pH 8.0), and dialyzed overnight against PBS. The anti-VCP antibody content in the eluates 
and flowthrough was tested by ELISA. 
Normal immunoglobulin preparations were obtanined from normal human serum by 50% 
ammonium sulfate precipitation followed by resuspension of precipitate, extensive dialysis 
with PBS. and affinity chromatography on Protein G. Column eluates were neutralised with 
Tris 1M (pH 8.0) and dyalised overnight against PBS. 
 
Peripheral blood cells isolation. 
Peripheral blood mononuclear cells and granulocytes have been obtained from buffy coat.  
Neutrophils were isolated  using Ficoll-Hypaque density centrifugation. All neutrophils 
preparations contained fewer than 2% monocytes, B and T lymphocytes as evaluated by flow 
cytometry using anti-CD14, anti-CD19 and anti-CD3 antibodies. 
Lymphocytes B and monocytes have been purified from Ficoll-Paque isolated PBMC, by 
means of immunomagnetic selection with CD20 and CD14 magnetic microbeads, 
respectively (Miltenyi Biotech, Bergish Gladbach, Germany). 
All CD20+ and CD14+ preparations contained less than 3% of other cells. 
 
Viral preparation 
Viral preparations of infectious EBV strains from the B95-8 marmoset cell line were 
produced by standard procedure [29]. Briefly, B95-8 cells were grown in RPMI medium 
supplemented with 10% heat inactivated FBS. When the viability of cell cultures reached 
20% or less, as determined by Trypan Blue-dye exclusion, cell free culture supernatants were 
 98
obtained and filtered through a 0.45 µm pore size filter and viral particles were purified by 
ultracentrifugation. Virus stocks were resuspended in PBS, aliquoted and stored at –80° C 
until use. Viral titers were quantitated by PCR (in collaboration with Dott. Fabrizio Maggi, 
Clinical Virology Unit, Department of Experimental Pathology, University of Pisa) 
 
EBV infection 
Cells were infected with EBV (105 transforming units) and cultured in complete medium in 
25 or 75 cm2 flasks. 
Neutrophils were incubated in Hanks Balanced Saline Solution (HBSS) supplemented with 
1% human serum and incubated with EBV at 4°C for 15 minutes to allow binding to the cell 
surface. Virus bound cells were then cultured for 20 hours at 37 °C. 
Monocytes were incubated in HBSS 1% FBS and incubated with EBV for 1 hour at 37°C to 
favour contacts with cells and then cultured for 20 hours at 37 °C. 
Before EBV infections, neutrophils and monocytes were incubated with Cytochalasin B 10 
mM to inhibit phagocytosis.  
 
Viral infection was checked by means of PCR in collaboration with Dott. Fabrizio Maggi. 
Before DNA extraction cells were pretrated with 0.05% Trypsin-0.5 mM EDTA in order to 
remove any remaining EBV particles adsorbed to cell surface. 
 
Preparation of cell lysates and immunoblotting 
Treated cells were harvested and lysed in Tris-HCl 20 mM, NaCl 150 mM, EDTA 5 mM, 
Triton X-100 1% and protease inhibitor cocktail. 
Cell lysate was mixed with SDS-PAGE sample buffer and subjected to SDS-PAGE under non 
reducing conditions, and blotted onto a polyvinylidene difluoride (PVDF) membrane 
(Hybond P, GE Healthcare, Little Chalfont, UK). 
Membrane strips were saturated for 30 minutes at room temperature in TBS containing 3% 
BSA or non fat dry milk and incubated overnight with anti-VCP antibodies purified from RA 
patients diluted at 50 µg/ml in TBS, Tween 20 1% (T-TBS) and then with anti-human IgG 
horseradish peroxidase conjugated antibody diluted at 0,2 µg/ml in T-TBS.  
Anti-Citrulline (modified) Detection Kit (Upstate Biotechnology, Lake Placid, NY) was used, 
following the manufacturer’s instructions, to detect deiminated proteins. This kit provides the 
reagents required for the detection of citrulline-containing proteins by Western blot analysis 
with the anti-Citrulline antibody. Detection is a two-step process in which citrulline-
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containing proteins immobilized on nitrocellulose or PVDF are formaldehyde-cross linked to 
the membrane to improve protein retention, followed by modification of citrulline residues 
with 2,3-butanedione monoxime and antipyrine in a strong acid solution to form a ureido 
group adduct. This ensures detection of citrulline-containing proteins regardless of 
neighbouring amino acid sequences. Detection of the modified citrulline proteins is 
subsequently performed using a standard immunoblot protocol with the anti-Citrulline and 
goat anti-rabbit IgG-HRP 
Anti-histone H3, anti-histone H4 and anti-histone H2a and H2b monoclonal antibodies (all 
from Advanced Biotechnologies, Columbia, MD) were used to detect histones. 
 
Peroxidase activity was visualised by means of enhanced chemiluminescence using 
SuperSIgnal West Dura Extended Duration Substrate (Pierce, Rockford, IL). Images were 
acquired and analysed using VersaDoc Imagin System and QuantityOne analysis software 
(both from Biorad, Hercules, CA) 
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RESULTS 
 
EBV infects preferentially B cells and epithelial cells from the orofarynx, binding the CD 21 
receptor with gp350. 
However, it has been described that EBV may infect also neutrophils and monocytes via 
different receptors apart from CD21. This transient infection may induce in target cells events 
such as apoptosis and consequent cell death. 
 
During apoptosis a number of intracellular events may occur, such as calcium ions 
mobilisation from intracellular store or calcium influx from extracellular compartments. 
Since an increase in calcium concentration may lead to activation of peptydilarginine 
deiminase, with the consequence of deimination of intracellular proteins, we hypothesised: 
- that transient EBV infection of neutrophils and/or monocytes may induce activation of PAD 
and deimination of intracellular proteins 
- that newly deiminated proteins may become target of ACPA. 
 
Granulocytes, B lymphocytes, monocytes from peripheral blood were infected using culture 
fluid of B95-8, a marmoset cell line producing infectious EBV particles. At the end of the 
infection period, cells were lysed, subjected to SDS-PAGE and elettroblotting, and 
nitrocellulose filters were incubated with anti-VCP antibodies purified from RA patients. 
Non infected cells were used as controls. 
 
Preliminary data, shown in Figure 11, suggested that anti-VCP antibodies bind a number of 
proteins characterised by low molecular weight (around 12-15 KDa), not recognised by 
control immunoglobulins; moreover, in some cases, such a binding is specific of EBV 
infected cells. 
Testing the cell lysates for the presence of citrullinated proteins, using anti-Citrulline 
(modified) Detection Kit, we observed that a protein migrating at the same molecular weight 
of the one recognised by anti-VCP antibodies is citrullinated. 
 
The molecular weight of this band is compatible with the molecular weight of histones (10-20 
KDa). 
Moreover, it is already known that histones can be deiminated in response to different stimuli 
[30, 31]. 
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Thus, cell lysates were incubated with monoclonal antibodies specific for different histones: 
anti-H2, anti-H3 and anti-H4 histones. 
Anti-H4 antibody bound a protein with a molecular weight compatible with a band recognised 
by anti-VCP antibodies and anti-modified citrulline antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Reactivity of anti-VCP purified antibodies (Anti-VCP 1 and VCP2 Ab), normal human 
IgG (NH IgG), anti MC kit and anti-H4 antibody with infected granulocytes (GI), lymphocytes B 
(LBI), monocytes (MI) and with non infected granulocytes (G), lymphocytes B (LB) and monocytes 
(M) lysate. 
 
 
 
 
 
These results suggested that during transient EBV infection of neutrophils, histones can be 
deiminated thus transforming these molecules into targets of ACPA in RA patients. 
 
 
 
G  GI  LB  LBI  M  MI G  GI  LB  LBI  M  MI G   GI   LB  LBI   M   MIG  GI  LB  LBI  M MI 
NH IgG Anti-VCP 1 Anti-VCP 2 Anti-H4 Anti-MC 
G  GI
LMW
18 KDa 
- 
28 KDa 
- 
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However, this hypothesis was not corroborated by confirmation experiments. 
In fact, in different cases no reactivity with anti-VCP was observed in the presence of binding 
with anti-histones antibodies and anti-modified citrulline antibody, or no reactivity with anti-
citrulline kit was observed in the presence of reactivity with anti-VCP antibodies and anti-
histone ( Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Reactivity of anti-VCP purified antibodies (Anti-VCP 1 and VCP2 Ab), anti MC kit and 
anti-H4 antibody with infected (IN) and non infected neutrophils (NIN) lysate. 
The spot  on the left (VCP 2µg/ml directly spotted on the nitrocellulose) represent the positive control 
for anti-MC kit 
 
Anti-VCP 
Ab 1 
Anti-VCP 
Ab 2 
Anti-MC 
kit 
Anti-H4 
Anti-MC 
kit 
VCP 
IN IN IN NIN NIN NIN IN NIN 
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DISCUSSION 
 
 
The reactivity of RA sera with a deiminated protein encoded by EBV raises the issue of the 
role of the virus in inducing ACPAs and opens up new perspectives that may help us to 
decipher the mechanisms leading to the production of these antibodies in RA. EBV is 
considered to be one of the environmental agents that contribute to the pathogenesis of RA. 
EBV infection is widespread, and 95% of all adults display serologic signs of a previous 
infection. It is known that patients with RA have elevated levels of antibodies to latent and 
replicative EBV proteins [6] and in particular to EBNA-1 [32, 33]. 
It has been convincingly demonstrated that peripheral T lymphocytes from patients with RA 
are not efficient in the killing of autologous EBV-infected lymphoblastoid B lines [8], and 
that the frequency of EBV-infected peripheral B lymphocytes is higher in patients with RA 
than in controls [9]. More recently, it was shown that the EBV DNA content in PBMCs from 
patients with RA is 10-fold higher than that in PBMCs from healthy individuals or from 
patients with other inflammatory arthritides [23]. Another study detected EBV infection in 
synovial tissue from patients with RA but not in patients with osteoarthritis [20, 22], although 
other investigators failed to confirm these findings [21]. Although it is not yet clear whether 
this viral overload is specific for EBV, it certainly could provide a chronic antigenic stimulus 
leading to the processing of viral proteins and the presentation of EBV-derived peptides. 
EBNA-1–specific CD4 T cells [34, 35], mainly of the Th1 phenotype [36], have recently been 
detected in healthy EBV carriers and may provide help for the production of antibodies 
directed to the different epitopes of this protein. In the presence of a higher EBV load, events 
such as apoptosis, infection, damage, or any stimulus involving calcium influx may activate 
PAD, which is highly expressed in RA synovia [37, 38], and induce the deimination of 
different proteins, including viral proteins. As a result, EBNA-1 may contain 
posttranslationally acquired deiminated sequences. Naive B cells specific for deiminated 
antigen and normally present in the B cell repertoire [39] could undergo affinity maturation 
with the help of EBNA-1–specific T cells, giving rise to the production of ACPAs that takes 
place in patients with RA. 
 
It has been observed that EBV may infect transiently neutrophils and monocytes, and that in 
these cells it can modulate a number of biological events (Table 5) 
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Modulating effects of EBV on phagocytes biological functions 
Phagocytes Dependent on viral adsorption 
Dependent on viral protein 
expression/replication 
Induction of IL-1α, IL-1β, IL-1RA, 
IL-8, MIP-1α expression 
Induction of cell death by 
apoptosis 
Neutrophils 
Priming effects on LTB4 release 
and superoxide production 
 
Induction of IL-6 expression Induction of IL-1b 
Induction of GM-CSF 
Inhibition of TNF-a and MIP-
1a expression 
Priming effects on LTB4 and C4 
biosynthesis 
Inhibition of PGE2 
biosynthesis 
Monocytes 
Inhibition of DC development Inhibition of phagocytosis 
 
Table 5. Modulating effects of EBV on phagocytes biological functions 
 
Thus, we tested the hypothesis that EBV may infect neutrophils or monocytes, inducing 
different events all culminating with protein deimination.  
 
Unfortunately, the data we obtained were conflicting. 
In fact the first set of experiments, suggestive of the role of EBV infection in the deimination 
of intracellular proteins in neutrophils, was not confirmed in the second group of experiments. 
 
Analysing all the steps of the experiments a number of critical points can be individuated. 
 
First of all, the incubation of EBV infectious particles with cells did not result in the same rate 
of infection, with consequent differences in the downstream events. 
In fact, we observed notable differences among experiments in the number of apoptotic cells 
obtained after infection. 
 
Another critical point has been identified in the chemical modification of citrullyl residues in 
proteins adsorbed onto nitrocellulose filters, during the anti-MC kit usage. 
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Testing an in vitro deiminated protein as control, we observed a great inter-assay variability 
with notable differences in the ECL signal intensity. In a complex system like the one we are 
studying, in which a cascade of events are taking place and the final product we are trying to 
detect is present in minute amounts, such a variability may deeply affect the results. 
 
However, data in the literature and the initially encouraging results prompted us to continue in 
this field of research. 
A great amount of work is needed to shed light on the possible role of EBV in the 
pathogenesis of RA, and this approach may give some contribution. 
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CHAPTER 6 
CONCLUSIONS 
 
 
The wide number of results obtained during the last 10 years in the attempt to clarify the 
pathogenesis of RA corroborate the idea that citrullination is intimately involved in the 
pathophysiology of rheumatoid arthritis and complete a model (the rheumatoid arthritis cycle) 
for the development and chronic nature of this disease [1]. 
 
 
 
The rheumatoid arthritis (RA) cycle [1]. Model for the role of protein citrullination in the pathophysiology of 
RA. The various aspects of the five major steps are depicted. Step 1, entry and death of inflammatory cells in the 
synovium; step 2, peptidylarginine deiminase (PAD) activation and protein citrullination; step 3, immune 
response to citrullinated antigens; step 4, formation of citrullinated immune complexes and their effects; step 5, 
recruitment of new inflammatory cells. ACPA, anti-citrullinated protein/peptide antibody. 
 
 
 
STEP 1 
A by itself innocent inflammation of a tissue in the body leads to infiltration of inflammatory 
cells containing PAD enzymes.  
During activation, the intracellular concentration of calcium ions may increase, thus allowing 
for intracellular deimination of proteins. 
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Moreover, after activation these cells undergo apoptosis (another event linked to intracellular 
increase of calcium concentration), physiologically die and are cleared by other phagocytes. If 
apoptosis is massive, that is in the presence of infection or defects in the clearance system, 
some apoptotic cells may become necrotic, thereby releasing intracellularly citrullinated 
proteins (histones, vimentin, viral proteins, alpha-enolase) and exposing PAD enzymes to 
activating extracellular concentration of calcium. PAD’s can subsequently citrullinate proteins 
like fibrin and collagen. 
This process is not confined to the joints but it may occur in every inflamed human tissue (for 
example in bronchoalveolar cells from smokers). 
The presence of even high amounts of citrullinated proteins in tissues will not by itself lead to 
chronic inflammation since in almost the totality of cases citrullinated proteins will be 
removed without activating a humoral immune response. 
 
 
STEP 2 
In those individuals who are able to present citrullinated fragments of proteins to T cells via 
certain HLA molecules, a B cell response to citrullinated antigens can be generated resulting 
in the production of high affinity IgG ACPA. B cells may be activated outside the joints and 
enter in the joints when local inflammation occurs or as a result of vascular leakage. 
Alternatively, the activation may occur locally within the inflamed joint. Irrespective of the 
site of activation it has been shown that ACPA can produced locally in the RA joints, where 
they can react with abundant citrullinated proteins. 
Such a mechanism is supported by data obtained with citrullinated fibrinogen and a 
citrullinated peptide derived from vimentin [2] and [3] 
 
 
STEP 3 
After their production in/entry into the inflamed synovium, ACPAs can react with the 
abundantly available citrullinated antigens. 
The resulting immune complexes will stimulate the inflammatory process by activation of 
complement and further recruit and activate granulocytes and mononuclear cells via both 
complement receptors and Fcγ receptors dependent pathways [4]. In this way ACPA 
contribute to the perpetuation of joint inflammation and to the chronicity and severity of RA. 
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STEP 4 
New monocytes and granulocytes will enter the synovium, where they will be activated, 
subsequently die and release new activated PAD molecules. A new round of citrullinated 
antigens and ACPA production will take place, leading to a new flare of inflammation. 
The continuation of this vicious circle for years, eventually accompanied by fresh traumas or 
environmental events that stimulate inflammation, will ultimately lead to a chronic 
inflammation that is the main feature of the disease we define RA.  
 
 
 
The results reported in this thesis perfectly fit in this scheme, contribute to the understanding 
of some crucial aspects of the pathogenesis of RA and challenge some “traditional” views on 
gene-environment interaction in this disorder. 
The data we presented, together with several lines of evidence provided by other groups, 
suggest that EBV infection should be considered among the triggers of RA. 
The analysis of genetic control of the immune response to viral citrullinated peptides suggests 
to re-evaluate the role of HLA-SE alleles as classic immune response genes; under this 
respect, T cells helper for ACPA production should be searched outside those (elusive!) 
specific for citrullinated epitopes. A complete evaluation of citrullinated proteins in tissues by 
proteomics may represent the set of key experiments able to shed light on these issues. 
Our data have also a number of practical applications. According to our results, the immune 
response to citrullinated antigens is heterogeneous, so that the usage of different citrullinated 
substrates may improve sensitivity of APCA assays. 
Moreover, we detected ACPA of IgM and IgA subclasses in absence of ACPA IgG. 
Taken together, these results can be the proof of concepts for the use of multiarray assays in 
the diagnosis of rheumatoid arthritis, that is detection at the same time of ACPA specific for 
diverse antigens and of different isotypes. 
Alongside with the development of this technology, that is extremely complex and expensive, 
we can envision the set up of assays suitable for a first screening in doctor’s office. 
More rapid assays, as for example the lateral flow assays where a simple blood drop is 
delivered directly onto the membrane, allowing an rapid (10 minutes) qualitative evaluation 
and an immediate diagnosis, meet these requirements. 
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In conclusion, the results obtained in this PhD project suggest a modification of the RA cycle 
proposed by van Venrooij [1] as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 EBV transient infection 
Direct HLA SE stimulation of cell Evaluation of  
all ACPA isotypes 
with different substrates 
 
MULTIARRAYS 
EBV transient infection 
 115
REFERENCES 
 
1. van Venrooij WJ and Pruijn GJM. An important step towards completing the 
rheumatoid arthritis cycle. Arthr Res Ther. 2008; 10:117-120 
2. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, 
Robinson WH, Cairns E: Arthritis induced by posttranslationally modified 
(citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008, 205:967-979 
3. Hill JA, Wang D, Jevnikar AM, Cairns E, Bell DA: The relationship between predicted 
peptide-MHC class II affinity and T-cell activation in a HLA-DRbeta1*0401 transgenic 
mouse model. Arthritis Res Ther 2003, 5:40-48 
4. Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH, Gregersen 
PK, Robinson WH: Circulating immune complexes contain citrullinated fibrinogen in 
rheumatoid arthritis. Arthritis Res Ther 2008, 10:94-99 
 116
 
 117
SUMMARY 
 
Rheumatoid arthritis (RA) sera contain antibodies specific for deiminated peptide/proteins 
(ACPA). 
The deimination (or citrullination) is a post-translational modification catalysed by the 
calcium dependent enzyme peptidylarginine deiminase: an arginyl residue within protein is 
converted to a cytrullyl residue, with the consequent loss of a net positive charge. 
Citrullination is a physiologic event, occurring during cell differentiation, and particularly in 
inflammation and cell death; on the contrary, antibodies directed towards citrullinated 
proteins/peptides are highly specific for RA. 
A number of endogenous proteins have been found to be citrullinated and target of ACPA 
Recently, a viral peptide corresponding to the sequence 35-58 Epstein Barr Nuclear Antigen-1 
containing citrulline in place of arginine (VCP – Viral Citrullinated Peptide) has been shown 
to be a specific probe for the detection of ACPA. 
To analyze the immune response to citrullinated Epstein-Barr antigens in RA, we tested 
peptides derived from different viral proteins and characterised by different rates of 
citrullination. 
Studying a large panel of peptides, we found high reactivity against another deiminated viral 
peptide (DVP).  
Thus, we measured anti-DVP antibodies of IgG, IgM and IgA isotype in 100 normal sera, 107 
RA and 196 disease controls. 
Setting the threshold value at the 99° percentile of the normal population, IgG anti-DVP were 
found in 65%; IgM anti-DVP in 44%; and IgA anti-DVP in 48% of RA patients. In some 
cases IgM or IgA were present in the absence of IgG; moreover, anti-DVP and anti-VCP 
antibodies were found to be overlapping but distinct populations.  
 
Rheumatoid arthritis is a multifactorial disease. Among genes, the major contribution to RA 
susceptibility is given by HLA-DRB1 alleles encoding the “shared epitope” (SE) sequences. 
The presence of these alleles is strictly associated with the production of ACPAs. However, 
the genetic background underlying the production of single ACPA specificities has not been 
thoroughly investigated. 
Thus, we analysed the reactivity to two different viral citrullinated peptides (VCP and DVP) 
and studied their association with genetic variants within HLA-DRB1 SE alleles in a RA 
Caucasian population. 
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One hundred and seventy-two French RA patients were characterized in terms of HLA-DRB1 
genotype, anti VCP-A and anti-DVP antibodies.  
HLA-DRB1 SE alleles were classified into four SE+ groups (S1, S2, S3P, S3D) and one SE- 
group (X) according to a new classification of HLA-DRB1 alleles, “reshaping the shared 
epitope (SE) hypothesis”. 
Anti-viral citrullinated peptides antibodies were assessed by home made ELISA on VCP and 
DVP coated plates. 
We found that anti-VCP and anti-DVP antibodies showed a trend in association to HLA-SE 
alleles but not significant (odds ratio > 1, P>0.05). 
However, subgrouping the SE alleles according to the new classification, the presence of anti-
VCP or anti-DVP antibodies is associated with S2 allele (OR>1, P<0.05). Analysing the 
contribution of single SE alleles belonging to the S2 subgroup, anti-VCP and anti-DVP 
antibodies are associated with HLA-DRB1 *0401 (OR>1, P<0.05). 
We have tested the peptides for their capacity to bind various HLA-DR molecules. In no 
instance we found that any of the peptides bound any of the DR molecules at the highest dose 
tested. 
Therefore, these results challenge the role of HLA-SE in the pathogenesis of rheumatoid 
arthritis. More studies are needed to clarify whether HLA-SE may act as a classic immune 
response gene, thus presenting citrullinated peptide to T cells or whether they may play other 
roles, directly stimulating immune system cells. 
 
RIASSUNTO 
 
Sieri di pazienti affetti da artrite reumatoide contengono anticorpi specifici per 
peptidi/proteine deiminate (ACPA). 
La deiminazione (o Citrullinazione) è una modificazione post-traslazionale catalizzata da un 
enzima calcio dipendente, la peptidil arginin deiminasi (PAD): un residuo di arginina 
all’interno della proteina viene convertito in un residuo di citrullina mediante una 
deiminazione, con la conseguente perdita di una carica positiva. 
La citrullinazione è un evento fisiologico che si verifica durante il differenziamento cellulare, 
ma anche, e in particolar modo, nell’infiammazione e nella morte cellulare; al contrario, gli 
anticorpi diretti verso epitopi citrullinate sono estremamente specifici dell’artrite reumatoide. 
Numerose proteine endogene possono essere citrullinate e diventare target degli ACPA. 
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Recentemente, un peptide virale corrispondente alla sequenza 35-58 dell’Epstein Barr Nuclear 
Antigen-1, contenente citrulline invece di arginine (VCP – Viral Citrullinated Peptide) è stato 
descritto essere un substrato specifico per la determinazione degli ACPA nel siero di pazienti 
con AR. 
Al fine di far luce sulla risposta immune a peptidi citrullinati di origine virale, abbiamo 
analizzato numerosi peptidi virali derivati da differenti proteine e caratterizzati da diverso 
grado di deiminazione. 
Lo studio di un vasto pannello di peptidi ci ha permesso di rilevare una elevata reattività verso 
un particolare peptide di origine virale (definito DVP – deiminated viral peptide). 
Abbiamo analizzato la presenza di anticorpi anti-DVP degli isotipi IgG, IgM e IgA in 100 
sieri di soggetti normali, 107 di AR e 196 sieri di patologie di controllo. 
Ponendo il valore soglia al 95° percentile della popolazioni di soggetti sani, IgG anti-DVP 
sono state rilevate nel 65% dei pazienti con AR, IgM nel 44% e IgA nel 48%. In alcuni casi 
IgM e IgA anti-DVP sono risultati presenti in assenza di IgG. Inoltre l’analisi ha dimostrato 
che le popolazioni di anti-VCP e anti-DVP sono sovrapposte ma comunque distinte. 
 
L’artrite reumatoide è una patologia multifattoriale. Tra i geni predisponesti, il contributo 
maggiore alla suscettibilità all’AR viene dagli alleli del HLA-DRB1 che codificano per una 
sequenza definita “shared epitope”. L’espressione di tali alleli è strettamente associata alla 
produzione di ACPAs. Il background genetico alla base della produzione degli ACPA, 
tuttavia, resta ancora da chiarire. 
A tale scopo abbiamo analizzato la risposta verso duye differenti peptidi virali citrullinate 
(VCP e DVP) e studiato la loro associazione con le varianti genetiche dell’HLA-DRB1 SE in 
una popolazione caucasica di pazienti con AR. 
Centosettanta due pazienti con AR sono stati caratterizzati per gli alleli HLA-DRB1 e per gli 
anticorpi anti-VCP e anti-DVP. 
Gli alleli HLA-DRB1 sono stati classificati in quattro gruppi SE+ (S1, S2, S3P, S3D) ed un 
gruppo di SE- (X), secondo la nuova classificazione di du Monctel. 
Gli anticorpi anti-VCP e anti-DVP sono stati determinati mediante homemade ELISA. 
Abbiamo evidenziato che esiste un trend di associazione tra la presenza degli alleli SE e la 
presenza di anticorpi anti-VCP e anti-DVP (odds ratio>1) ma che non raggiunge la 
significatività statistica (P>0.05). 
Analizzando il contributo dei singoli sottogruppi, abbiamo osservato che la presenza di anti-
VCP e anti-DVP si associa fortemente con la espressione degli alleli del sotto gruppo S2 
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(OR>1, P<0.05). Analizzando il contributo dei singoli alleli abbiamo evidenziato che 
l’espressione dell’allele HLA-DRB1*0401 aumenta la probabilità di produzione di anti-VCP 
e anti-DVP (OR>1, P<0.05). 
Abbiamo quindi analizzato la capacità di molecole di HLA-DRB1 purificate di legare i 
peptidi virali citrullinate. In nessun caso abbiamo osservato legame dei peptidi. 
Per concludere, questi risultati mettono in dubbio il ruolo degli alleli HLA-SE nella 
patogenesi della AR. Numerosi altri studi saranno necessari per chiarire se gli alleli HLA SE 
agiscono come un classico gene della risposta immune, coinvolti nella presentazione di 
peptidi citrullinate a cellule T oppure se le molecole HLA SE+ possano giocare altri ruoli, 
stimolando direttamente le cellule del sistema immune. 
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